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The field of drug delivery is rapidly expanding to bridge the gap between novel drugs that are created and their
effective entry into diseased tissue. In one growing area of research, synthetic polymers are being utilized to
meet these needs. The precise control over their chemistry allows polymers to be tuned to the drug delivery
application and make them attractive candidates for research. The focus of this dissertation is to engineer
responsive polymersomes for drug delivery and understand their ability to reduce drug toxicity, increase
absorption in diseased cells and tissue, and control the release of drug in vitro and in vivo. Gemcitabine, a
nucleoside analog, was encapsulated in the aqueous core of nano-polymersomes composed of the
biodegradable and biocompatible polymer PEO-PCL, and the in vitro toxicity of this novel drug delivery
construct was tested against Panc-1 cells. The polymersome formulation performed at par with the free drug
with one-log cell killing at 1 Ã¬M of gemcitabine. The polymersome was also able to control the release of
gemcitabine, and this release was modulated by the degradation kinetics of the ester linkages in the
membrane. Photodynamic therapy was performed against OVCAR-5 (ovarian cancer) cells. A hydrophobic
photosensitizer, benzoporphrin derivative monoacid A (BPD-MA) was encapsulated the in the membrane of
polymersomes composed of PEO14-PBD22 (OB14.5) polymer, and its phototoxicity was compared to an
existing photosensitizer formulation called verteporfin that is currently used in the clinic for age-related
macular degeneration (AMD). The polymersome formulation outperformed verteporfin both at the in vitro
and in vivo level. Additionally, we investigated the photorupture of giant polymersomes encapsulating a near
IR fluorophore (porphyrin dimer, PZn2) in the hydrophobic membrane and dextran in the aqueous lumen.
Polymersomes synthesized from softer polymers released more of a reporter dye than stiffer polymersomes
when illuminated with 690 nm of light. Finally, we investigated the fractionation of giant polymersomes in a
deterministic lateral displacement device and developed a hydrodynamic model to predict this fractionation
based on the attractive and repulsive forces experienced by the polymersome.
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ABSTRACT 
 
MULTI-FUNCTIONAL POLYMER VESICLES: APPLICATIONS IN DRUG DELIVERY 
AND PHOTODYNAMIC THERAPY 
Nimil Sood 
Daniel A. Hammer, Ph.D. 
The field of drug delivery is rapidly expanding to bridge the gap between novel drugs 
that are created and their effective entry into diseased tissue. In one growing area of 
research, synthetic polymers are being utilized to meet these needs. The precise control 
over their chemistry allows polymers to be tuned to the drug delivery application and 
make them attractive candidates for research. The focus of this dissertation is to 
engineer responsive polymersomes for drug delivery and understand their ability to 
reduce drug toxicity, increase absorption in diseased cells and tissue, and control the 
release of drug in vitro and in vivo. Gemcitabine, a nucleoside analog, was encapsulated 
in the aqueous core of nano-polymersomes composed of the biodegradable and 
biocompatible polymer PEO-PCL, and the in vitro toxicity of this novel drug delivery 
construct was tested against Panc-1 cells. The polymersome formulation performed at 
par with the free drug with one-log cell killing at 1 µM of gemcitabine. The polymersome 
was also able to control the release of gemcitabine, and this release was modulated by 
the degradation kinetics of the ester linkages in the membrane. Photodynamic therapy 
was performed against OVCAR-5 (ovarian cancer) cells. A hydrophobic photosensitizer, 
benzoporphrin derivative monoacid A (BPD-MA) was encapsulated the in the membrane 
of polymersomes composed of PEO14-PBD22 (OB14.5) polymer, and its phototoxicity 
was compared to an existing photosensitizer formulation called verteporfin that is 
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currently used in the clinic for age-related macular degeneration (AMD). The 
polymersome formulation outperformed verteporfin both at the in vitro and in vivo level. 
Additionally, we investigated the photorupture of giant polymersomes encapsulating a 
near IR fluorophore (porphyrin dimer, PZn2) in the hydrophobic membrane and dextran 
in the aqueous lumen. Polymersomes synthesized from softer polymers released more 
of a reporter dye than stiffer polymersomes when illuminated with 690 nm of light. 
Finally, we investigated the fractionation of giant polymersomes in a deterministic lateral 
displacement device and developed a hydrodynamic model to predict this fractionation 
based on the attractive and repulsive forces experienced by the polymersome.  
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1 Introduction to Synthetic Polymers as 
Drug Delivery Vehicles and the 
Specific Aims of this Dissertation 
 
 
1.1 Challenges in Drug Delivery 
With significant advancement in the field of medical science, new classes of 
pharmaceuticals and biologics are paving the way for the rapid evolution of drug delivery 
technologies. The underlying challenges in drug delivery, however, have remained fairly 
constant. Drug solubility and stability in the body, method of administration (oral, 
intravenous, transdermal, intramuscular, etc.), and drug absorption, distribution, 
metabolism, and elimination all are critical parameters that determine the overall efficacy 
and toxicity of a drug. The design of new drugs takes into account these considerations. 
Because of the complexity of new treatments, engineering smart delivery vehicles is 
often done in tandem with drug development. Figure 1-1 illustrates the fate of a drug and 
drug delivery vehicle from its introduction into the body to its ultimate metabolization and 
elimination. Stable drug carriers must navigate the harsh in vivo environment to 
successfully deliver the therapeutic payload to the appropriate site. 
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Figure 1-1: Diagram illustrating how drugs are absorbed, distributed, metabolized, and excreted from the 
body. Adapted from [1]. 
 
The work presented in this thesis focuses on the utility of synthetic polymers for 
the delivery of therapeutic drugs to cancer cells. The next section outlines the use of 
polymersomes, self-assembled polymer vesicles, for drug delivery applications. 
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1.2 Introduction to Polymersomes as Drug Delivery Vehicles 
Polymersomes are self-assembled vesicles composed of amphiphilic block 
copolymers. In aqueous solution, these polymers undergo spontaneous reordering that 
yield mesoscopic structures ranging in size from hundreds of nanometers to tens of 
microns [2]. Much like the packing parameter [3] (𝑣/𝑎0𝑙𝑐 ) established for the self-
assembly of lipids in solution – where the ratio of the hydrophobic tail volume 𝑣 to the 
product of the head group area 𝑎0 and hydrophobic tail length 𝑙𝑐  give different structures 
in solution ranging from micellar to bilayer vesicles – a general rule of thumb exists for 
polymersomes as well. The hydrophilic to total mass fraction guides the assembly of 
various structures. This is highlighted in Table 1-1. 
 
Table 1-1: General guidelines for the self-assembly of block copolymers in solution. Adapted from [2]. 
𝑓ℎ𝑦𝑑𝑟𝑜𝑝ℎ𝑖𝑙𝑖𝑐 Shape Factor 
𝑓 < 25% Inverted microstructure 
25% < 𝑓 < 35% Bilayer vesicle 
𝑓 > 45% Micelle 
 
Polymersomes have significant advantages over liposomes. While both vesicles have an 
aqueous core and hydrophobic membrane, the hyperthick polymer membrane can 
encapsulate a much larger payload of hydrophobic molecules. Lipid membranes have a 
thickness of around 3 nm whereas polymersomes can have varying membrane 
thicknesses ranging from  8 nm to 21 nm [4]. Polymersome membranes are also 
mechanically more robust than liposome membranes. Typical values of membrane 
elastic moduli, as determined from micropipette aspiration, are around 100 dyne/cm for 
polymersomes and 150 to 1000 dyne/cm for liposomes [4, 5]. The surface chemistry of 
polymersomes can be readily altered to include targeting moieties. Previous work has 
been done to conjugate a TAT peptide on the surface of polymersomes to enhance the 
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uptake of vesicles by dendritic cells [6]. The improved mechanical robustness, 
hydrophobic encapsulation potential, and surface modification potential make 
polymersomes ideal candidates for targeted drug delivery applications.  
 
1.3 Specific Aims 
Aim 1: Develop controlled release nano-polymersome platform for the encapsulation 
and release of chemotherapeutic drug and determine toxicity in cancer cells. 
Aim 2: Quantify the release of an encapsulated fluorescent dye from giant 
polymersomes due to photo-initiated rupture. 
Aim 3: Encapsulate a photosensitizer in nano-polymersomes for photodynamic therapy 
and assess the in vitro and in vivo toxicity of the polymersomes. 
Aim 4: Develop a force-based model for understanding and predicting polymersome 
fractionation in a deterministic lateral displacement microfluidic device. 
 
1.4 Description of Dissertation 
This dissertation is composed of six chapters and describes the efforts to create 
controlled release polymersomes for the delivery of therapeutic molecules to in vitro or in 
vivo cancer models. 
 
Chapter 2 presents the preparation and characterization of nano-polymersomes 
synthesized from PEO-PCL that encapsulate a chemotherapeutic drug called 
gemcitabine. Like many other chemotherapeutic drugs, gemcitabine has a short half-life 
in the blood and severe dose limiting toxicities. Encapsulating gemcitabine within 
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polymersomes can mitigate these side effects, increase the blood circulation time, and 
produce greater toxicity at the cancer site. We can passively control the release of 
gemcitabine from the polymersomes by taking advantage of the PCL block degradation 
under acidic conditions. 
 
Chapter 3 presents an extension of controlled release polymersomes. In this 
chapter, we illustrate and quantify the photoresponsiveness of giant polymersomes that 
contain a hydrophobic solute in the membrane (porphyrin) and a hydrophilic solute in the 
aqueous lumen (dextran). Under certain illumination conditions, these polymersomes 
undergo membrane deformation and rupture. This work has implications in the field of 
drug delivery since we can actively control the release of encapsulated molecules.  
 
Chapter 4 presents the work done to synthesize and characterize nano-
polymersomes that encapsulate a photosensitizer for photodynamic therapy (PDT). PDT 
provides an interesting approach to cancer therapy because the cytotoxic agent is not a 
small molecule drug but actually singlet oxygen. Singlet oxygen is generated locally by 
first administering a photosensitizer, and then illuminating the diseased tissue with a 
specific wavelength of light. A polymersomal formulation of the photosensitizer provides 
several advantages over current formulations, with the additional benefit of having a dual 
drug delivery vehicle encapsulating both a photosensitizer in the hydrophobic membrane 
and chemotherapeutic drug in the aqueous lumen. 
 
Chapter 5 is a departure from the topic of nanoparticle drug delivery. In this 
chapter, I discuss the experimental and computational modeling work done to 
understand the fractionation of giant polymersomes in a deterministic lateral 
displacement microfluidic device. Synthesizing monodisperse polymersomes form thin-
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film rehydration is extremely challenging. Other methods of synthesizing polymersomes 
(emulsion techniques, electroporation) result in a monodisperse population but low yield. 
Combining the rehydration technique with a fractionation will give a large number of 
polymersomes of a desired size. 
 
Finally, Chapter 6 details the major findings and future directions of the work 
presented in this dissertation. 
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2 Biodegradable Polymersomes for the 
Delivery of Gemcitabine to Panc-1 
Cells 
 
 
2.1 Summary 
Traditional anti-cancer chemotherapy often displays toxic side effects, poor 
bioavailability, and a low therapeutic index. Targeting and controlled release of a 
chemotherapeutic agent can increase drug bioavailability, mitigate undesirable side 
effects, and increase the therapeutic index. Here we report a polymersome-based 
system to deliver gemcitabine to Panc-1 cells in vitro. The polymersomes were self-
assembled from a biocompatible and completely biodegradable polymer, 
poly(ethyleneoxide)-poly(caprolactone), PEO-PCL. We showed that we can encapsulate 
gemcitabine within stable 200 nm vesicles with a 10% loading efficiency. These vesicles 
displayed a controlled release of gemcitabine with 60% release after 2 days at 
physiological pH. Upon treatment of Panc-1 cells in vitro, vesicles were internalized as 
verified with fluorescently labeled polymersomes.  Clonogenic assays to determine cell 
survival were performed by treating Panc-1 cells with varying concentrations of 
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unencapsulated gemcitabine (FreeGem) and polymersome-encapsulated gemcitabine 
(PolyGem) for 48 hours. 1 μM PolyGem was equivalent in tumor cell toxicity to 1 μM 
FreeGem, with a one log cell kill observed. These studies suggest that further 
investigation on polymersome-based drug formulations are warranted for chemotherapy 
of pancreatic cancer. 
 
2.2 Introduction 
 
Pancreatic adenocarcinoma is the fourth highest cause of cancer death with a 5-
year survival rate of less than 6% [1].  Despite the use of surgery, radiation and/or 
chemotherapy [2], local recurrence and metastasis invariably occur.  The causes of 
resistance of pancreatic tumors are not completely understood. The inability to deliver 
adequate adjuvant therapy due to local normal tissue toxicity, limitations caused by 
tumor microenvironment (hypoxia, pH), and active drug export out of tumor cells likely 
cause this resistance [3-4].  Modifications to the delivery of chemotherapeutics that 
improve the therapeutic ratio (TR) are highly desirable in order to allow higher drug 
delivery while minimizing toxicity to normal tissues. 
 
Gemcitabine is a commonly-used water soluble anticancer agent that acts as an 
anti-metabolite; it is considered an efficacious addition to radiation therapy in pancreatic 
cancer [5]. Gemcitabine is an S-phase deoxycytidine analog (2’,2’-
difluorodeoxycytidine). Its mechanism of action involves competitive incorporation into 
DNA, masked termination (causing termination of DNA synthesis without being excised 
out of the strand), and self-potentiation (promoting its own activity by inhibiting regulatory 
enzymes involved in DNA synthesis). Like most chemotherapeutics, its use has 
significant limitations. Gemcitabine is rapidly metabolized in the blood stream with a 
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short plasma half-life (for short infusions, 32 - 94 min) and has substantial side effects 
that limit the dose that can be given, especially when combined with radiation therapy 
[6]. In a phase 1 study, concurrent application of gemcitabine and radiation caused 
nausea, vomiting, dehydration and gastric ulceration resulting in a 44% hospital 
admission rate [7]. These side effects are much greater for concurrent therapy than for 
just radiation, which has been linked primarily to nausea. Encapsulation of gemcitabine 
in a carrier vehicle has the potential to reduce dose-limiting side effects while improving 
the drug delivery to the tumor.  The latter includes increased circulation time and 
preferential accumulation in tumor due to the enhanced permeability and retention (EPR) 
effect [8]. 
 
 Encapsulation of gemcitabine to address the challenges of rapid blood 
metabolism and low therapeutic ratio has been previously investigated. In one study, 
gemcitabine loaded in sonochemically-prepared bovine serum albumen (BSA) 
microspheres, was evaluated for cell killing in renal cancer in vitro [9]. These 
microspheres exhibited poor dynamics of release and were unable to take advantage of 
the EPR effect observed in solid tumors due to their large size (~1 μm diameter), an 
effect which requires 150-300 nm particles in diameter [8]. In another study, albumin 
nanospheres were loaded with gemcitabine [10]; this delivery system also had poor 
release kinetics with 100% of the drug being released in 24 hours. In a third study, 
encapsulated gemcitabine within poly(ethylene glycol)-poly(DL-lactic acid) (PEG-PDLLA) 
nano-vesicles showed toxicity against SW1990 pancreatic cells [11]. The vesicle 
morphology and size of these vesicles were very variable.  
 
Polymer vesicles, or polymersomes, are self-assemblies of amphiphilic block 
copolymers that can encapsulate both hydrophobic and hydrophilic compounds [12-13]. 
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Their highly tunable chemistry allows for diverse functionalities and applications [14]. 
Polymersomes possess superior biomaterial properties compared to their lipid 
counterparts (liposomes) including greater stability, storage capacity, release 
characteristics, and plasma circulation times [15-18]. The hydrophilic block is often 
composed of poly(ethylene oxide) (PEO) head groups, which helps reduce non-specific 
interactions with blood proteins due to their hydrophilicity and steric hindrance effects. 
This greatly reduces opsonization of nanoparticles and increases their plasma circulation 
time. Several biodegradable hydrophobic blocks can be utilized for drug delivery 
including polycaprolactone (PCL) and polylactide (PLA) for polymersomes and 
polylactic-co-glycolic acid (PLGA) for nanoparticles [14, 19-21]. PCL has several 
advantages over the other polymers including high permeability to small molecules, 
maintenance of neutral pH after degradation, ease of blending with other polymer 
blocks, and long-term and tunable erosion kinetics [22]. 
 
Recognizing the potential of PEO-PCL polymersomes for use in cancer 
treatment, this manuscript describes the novel use of PEO-PCL nano-polymersomes for 
gemcitabine encapsulation and in vitro delivery to Panc-1 cells. We investigated the 
polymersome release kinetics of gemcitabine, vesicle internalization by Panc-1 cells, 
and cell toxicity of PolyGems compared to standard gemcitabine (FreeGem). 
Polymersomes were internalized by Panc-1 cells and had equivalent cell toxicity at the 
same total dose when loaded with gemcitabine. These results suggest that PolyGems 
have the potential to be an attractive route to improve gemcitabine delivery in vivo. 
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2.3 Materials and Methods 
2.3.1 Materials 
Gemcitabine (Gemzar ®) was obtained from Eli Lilly and Company (Indianapolis, 
IN). Panc-1 cells were obtained from the ATCC. DMEM/F12 Ham’s (50/50) without 
phenol red was purchased from ZenBio (Research Park, NC). The meso-to-meso ethyne 
bridged (porphinato) zinc(II) trimer (PZn3) with a 9-methoxy-1,4,7-trioxanonyl substituent 
on one aryl group and a more hydrophobic 3,3-dimethyl-1-butyloxy substituent on the 
other, was synthesized as previously described [23]. Glacial acetic acid, methylene 
chloride, methylene blue for colony staining, phosphate buffered saline (PBS), sodium 
acetate trihydrate, and sodium chloride were purchased from Fisher Chemicals 
(Pittsburgh, PA). Polycarbonate extrusion membranes (13 mm) were purchased from 
Whatman (Piscataway, NJ). Centrifugal filter units were purchased from Millipore 
(Billerica, MA). Dialysis cassettes were purchased from Spectrum Laboratories (Rancho 
Dominguez, CA). 
 
2.3.2 PEO-PCL Preparation 
PEO-b-PCL with 45 and 105 monomer repeat units per block, respectively (MW 
= 14,000 g mol-1) was synthesized prior to this work [14]. The block co-polymer was 
generated via ring-opening polymerization of cyclic ε-caprolactone. Briefly, 
monomethoxypoly(ethylene oxide) (2k) was filled in a flame-dried flask under argon. 
Caprolactone monomer was injected into the flask via syringe and two drops of 
stannous(II) octoate was added to the reaction mixture. The reaction occurred at 130°C 
for 24 hours. The copolymer was isolated by dissolving the product in methylene 
chloride and precipitating in excess methanol/hexane at 4°C. The resulting powder was 
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dried further. The block co-polymer was purified via gel permeation chromatography and 
the molecular weight was determined by 1H NMR. 
 
2.3.3 Vesicle Preparation 
Polymersomes were synthesized by the thin film hydration method as described 
elsewhere [14]. Briefly, 200 μL of a 100 mg/mL PEO-PCL solution in methylene chloride 
were deposited on a roughened Teflon strip and allowed to dry overnight under vacuum. 
A 2.21 mg/mL (corresponding to 5:1 molar ratio of drug:polymer) solution of gemcitabine 
in 0.9% saline (~290 mOsm) was added to the film in a 20 mL vial in order to hydrate the 
polymer. Polymersomes were formed by one hour of sonication at 60°C and 5 
freeze/thaw cycles using liquid nitrogen. A narrow size distribution of polymersomes was 
obtained by successive extrusion through 400 nm, 200 nm, and 100 nm membranes 
using a thermobarrel extruder (Lipex Biomembranes, Vancouver, Canada) operating at 
65°C. Size was verified using a NanoZs Zetasizer (Malvern Instruments, Southboro, 
MA). 0.9% saline without drug was used as the hydration solution for control studies. For 
cellular uptake studies, polymersomes were loaded with the porphyrin-based near-IR 
fluorophore, PZn3 (λex = 785 nm, λem = 800 nm), at a molar ratio of 40:1 polymer to PZn3 
by cocasting the PZn3 with the polymer film. Before cell culture studies, vesicles were 
sterilized for 30 minutes via germicidal UV irradiation. 
 
2.3.4 Cryo-TEM 
Cryogenic Transmission Electron Microscopy was performed at the University of 
Pennsylvania in the Penn Regional Nanotechnology Facility (Philadelphia, PA). Lacey 
formvar/carbon grids (Ted Pella) were rinsed with chloroform to remove the formvar 
template and subsequently carbon coated with a Quorum Q150T ES carbon coater 
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(Quorum Technologies, United Kingdom). Grids were cleaned with hydrogen/oxygen 
plasma for 15 seconds using the Solarus Advanced Plasma System 950 (Gatan, 
Pleasanton, CA). Polymersome sample (2µL) was deposited on lacey formvar/carbon 
mesh grid (Ted Pella) and inserted into a cryoplunger (Gatan Cp3, Gatan). The sample 
was blotted by hand and plunged into liquid ethane. Samples were transferred to a 
cryoholder (Gatan CT3500TR, Gatan) and the cryoholder was immediately inserted into 
a JEOL 2010 TEM (JEOL) operating at 200 kV. Micrographs were imaged with an Orius 
SC200 digital camera. 
 
2.3.5 Vesicle Release Kinetics 
Nano-vesicles were prepared as described above. After extrusion, vesicles were 
concentrated to 0.5 mL volume using 3 kDa centrifugal filters made from regenerated 
cellulose. Additional removal of unencapsulated drug was performed via dialysis against 
a pH 5.0 sodium acetate/sodium chloride buffer (acidified with glacial acetic acid) or pH 
7.4 PBS buffer. Immediately following dialysis, 250 μL sample aliquots were placed in 
microdialysis tubes and stored in 22 mL of pH 5.0 or 7.4 buffer in a 37°C oven. At 
predefined time points, aliquots were taken from the buffer solution and read on a 
UV/Vis spectrophotometer at 270 nm (ε = 9.86 x 10-3 cm-1 μM-1). Aliquots were returned 
to the buffer to maintain a constant volume. 100% release was determined by addition of 
100 μL of a 1% Triton-X solution to the PolyGem vials after one week and the 
gemcitabine absorbance after overnight storage at 37°C was measured. 
 
2.3.6 Cell Culture 
At the time of receipt from the ATCC, cells were placed in cryo-vials and stored in 
liquid nitrogen for future use. Cells for study were defrosted using standard procedures. 
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New cell stock was defrosted at 6-month intervals. Panc-1 cells were cultured in 
DMEM/F12 Ham’s (50/50) without phenol red and with 12% fetal calf serum and 1% 
Pen/Strep. Cells were maintained in T-75 plastic culture flasks at 37°C in a humidified 
atmosphere containing 5% CO2 in air. Flasks were subcultured when they were 75 – 
90% confluent. Five minute exposure to 0.05% trypsin-EDTA was used to release 
attached cells from the tissue culture surface. 
 
2.3.7 In Vitro Cellular Uptake of Vesicles 
Fluorescent polymersomes were synthesized as described above. The 
concentration of PZn3 was determined by Beer’s Law using the established extinction 
coefficient ε(795nm) = 1.25 cm-1 μM-1 [24]. Panc-1 cells were plated in triplicate at 5,000 
cells per well in 96 well (black frame, clear well) cell culture plates (Isoplate-96 TC, 
Perkin Elmer). Cells were allowed to adhere overnight. The following day, varying 
concentrations of fluorescent polymersomes were added to wells and were incubated for 
12, 24, and 48 hours. At each time point, one plate was removed from incubation, 
washed three times with media to remove all polymersomes that were not internalized. 
Vesicles were illuminated on a LICOR Odyssey (λex = 488 nm, λem = 810 nm). A 
calibration curve was generated to relate the fluorescence signal from wells to the 
concentration of PZn3 to determine cellular uptake. Confocal laser scanning microscopy 
(CLSM) was used to visualize vesicle internalization in Panc-1 cells incubated with 
fluorescent polymersomes for 12 hours. An Olympus Fluoview FV1000 confocal 
microscope (Center Valley, PA) with a PLFLN 40x oil objective lens was used to obtain 
z-stacks of cells with a scan speed of 8.0 μs pixel-1 and step size of 1μm.  
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2.3.8 In Vitro Toxicity 
Panc-1 cells were plated onto 60 mm tissue culture dishes. After 48 hours, the 
plates were examined under the microscope for evidence of cell growth. Only plates 
containing of 50-90% confluent cells were used for study. Following the removal of spent 
media, the plates were rinsed with 2 mL of fresh media. The rinse media was then 
replaced with 2 mL of treatment solution (Polygem, FreeGem, or blank polymersomes). 
Dishes were incubated for an additional 48 hours. At the time of assay, cells were 
removed from the plate by incubating 2 mL of 0.05% trypsin-EDTA with the cells for 5 
minutes at 37°C. Trypsin was inactivated using fresh media with serum, and the total cell 
number was determined using a Coulter counter. A clonogenic assay was performed 
using standard techniques [25]. Plates were incubated for two weeks, with the goal of 
obtaining 25-250 colonies per plate. The surviving fraction was determined by 
normalizing the colony count of the treated condition by the initial cell number plated. 
The concentration of gemcitabine as reported for PolyGem represents the total 
encapsulated concentration. We corrected for the drug release relative to time, which 
was 60% release at 48 hours. The survival graphs were presented in absolute fractions 
with the maximal plating efficiency of untreated Panc-1 cells being 0.60. All comparisons 
were made to this value. Qualitative morphology of treated cells was observed using a 
Zeiss inverted microscope.  Panc-1 cells were treated with media, 5 μM FreeGem, 5 μM 
PolyGem, or 2.5 μM blank polymersomes. 
 
2.3.9 Statistical Analysis 
All experiments were performed in triplicate, except where noted. In vitro toxicity 
studies were performed in duplicate with varying amounts of initial cell plating to ensure 
the resulting colonies were within a countable range (50-200 colonies). Data were 
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reported as mean ± standard deviation and analyzed by Single Factor ANOVA, setting 
the level of significance at p < 0.05. 
 
 
2.4 Results and Discussion 
Despite the advancement of chemoradiation therapy for the treatment of 
pancreatic cancer, the 5-year survival rate continues to among be the lowest of solid 
tumors. Any improvement in the delivery of chemotherapeutics to pancreatic cancer 
should mitigate side-effects associated with treatment and improve the survival outlook 
for patients. In the studies reported herein, we created a prototype vehicle which could 
ultimately be capable of delivering gemcitabine, a potent pancreatic cancer drug, to 
pancreatic cancer. The major aim of this work was to perform a comparative in vitro 
study of the cell-killing efficacy of polymersome-encapsulated gemcitabine (PolyGem) 
and unencapsulated gemcitabine (FreeGem) on Panc-1 cells. 
 
 
2.4.1 Vesicle Preparation and Characterization 
Bioresorbable polymersomes were synthesized via the thin-film rehydration 
method from two FDA-approved polymers, poly(ethylene oxide) (PEO) and 
poly(caprolactone) (PCL), which were covalently linked to form a diblock copolymer. 
PEO-PCL self-assembled in a fashion such that the hydrophobic PCL block was 
embedded in the polymersome membrane and the PEO block was exposed on the outer 
vesicle surface and inner corona. Thin-film rehydration is particularly attractive for 
making polymersomes for biological applications as it does not require the use of 
potentially toxic organic solvents during the hydration step (as is employed in the solvent 
injection method) [26]. Figure 2-1 shows a schematic of our novel carrier. 
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Figure 2-1: Schematic representation of PolyGem. In aqueous solution, poly(ethylene oxide)-b-
poly(caprolactone) (PEO-PCL) self-assemble into spherical polymer vesicles (polymersomes), with the 
hydrophobic PCL chains orienting end-to-end to form the bilayer. The figure represents a uniaxial cross 
section of the polymersome, with gemcitabine ( ) encapsulated in the aqueous lumen. Vesicles can also be 
made to include PZn3 (    ) in the hydrophobic membrane.  
 
The size distribution of vesicles was measured using dynamic light scattering 
(DLS) and is shown in Table 2-1. Vesicles were serially extruded through 400, 200, 100, 
100, and 200 nm polycarbonate membranes to reduce the sample polydispersity. The 
average hydrodynamic diameter of PolyGems was 180 nm. The hydrodynamic diameter 
of blank polymersomes (181 nm) and PZn3-polymersomes (180 nm) did not statistically 
vary from PolyGems (p > 0.05). 
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Table 2-1: Hydrodynamic diameter and polydispersity of different polymersome formulations. 
 
 
Vesicles were stored at 4ºC and used in the studies within one week of 
preparation. We evaluated the stability of gemcitabine after sonication and freeze/thaw 
cycles by checking the absorbance of the drug before and after processing. There was 
no difference in the absorbance spectrum, indicating that the drug retained its structure. 
 
2.4.2 Vesicle Drug Release 
To improve the tumor-killing effect of drug delivery vesicles in vivo, maximal drug 
release should occur between 10 and 20 hours following injection, during which time the 
majority of vesicles have accumulated at the tumor and can cause toxicity [27]. In order 
to approximate the time constants of release of gemcitabine in vivo, we first explored the 
in situ release of gemcitabine from PolyGems under acidic (pH 5.0) and physiological 
conditions (pH 7.4) as shown in Figure 2-2. Approximately 20% of the gemcitabine is 
released from the PolyGems within the first few hours at both pHs. The concentration of 
gemcitabine released begins to level off at approximately day two, indicating stable and 
controlled release after an initial period up to 48 hours.  
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Figure 2-2: Cumulative in situ release of gemcitabine from PolyGem. Release was measured at pH 5.0 
and 7.4 at 37ºC. Gemcitabine was detected via UV/Vis spectroscopy for 7 days. N = 3 for each data point 
and the error bars represent standard deviation. 
 
The release curves are well fit by a function of the form c/c0 = α(1 – e 
– t/τ), where 
α is a lumped constant and τ is the characteristic time constant. This functional form can 
be derived from a 1-D analysis of drug diffusion across a semi-permeable membrane. 
Fitting this equation to the release curves in Figure 2-2 reveal that τpH5 is 12 hours and 
τpH7 is 16 hours (lower values of τ indicate more rapid release). These time constants 
describe the time required for 63% (1 – 1/e) of the drug to be released due to diffusion, 
and are functions of polymersome properties including geometric radius, membrane 
thickness, and diffusivity and partition coefficient of gemcitabine in the membrane. The 
time constants verify the quicker release observed at acidic conditions, with τpH5 equal to 
12 hours and τpH7 equal to 16 hours. The ideal time constant for release depends on the 
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time required for polymersomes to localize at a tumor site. Minimal drug should be 
released due to passive diffusion while the vesicles are still en route, and maximal and 
prolonged release should occur when vesicles have reached the tumor. As seen from 
the release curves, the majority of the gemcitabine was released within 2 days, which is 
consistent with the 10-20 hour window observed by Ahmed and coworkers [27]. 
 
A burst release of drug was observed during the first few hours, which was likely 
caused by the initially steep concentration gradient of gemcitabine present across the 
vesicle membrane, leading to a high initial diffusive flux. One explanation of this 
observation is that some entrapped gemcitabine in the outer PEO corona may have also 
contributed to the burst. Gemcitabine release was greater at all time points under acidic 
pH as compared to physiological pH. The PCL block is known to undergo hydrolysis of 
its ester linkages in solution, with a higher rate of degradation observed at acidic pHs as 
compared to physiological pHs [28-29]. Consequently, both membrane permeability and 
the diffusive flux of gemcitabine increased at pH 5.0. 
 
2.4.3 Cryo-TEM of Vesicles 
In order to understand the difference in observed release rate between vesicles 
at pH 5.0 and 7.4, we observed the structure of nanovesicles using cryo-TEM at the 
incubation different conditions. Figure 2-3 provides representative images of vesicles 
that have been incubated at either pH 7.4 (Figure 2-3A) or pH 5.0 (Figure 2-3B-D) for 12 
hours. The vesicles in Figure 2-3A have an even membrane thickness that is indicative 
of an intact membrane. The vesicles in Figure 2-3B-D have compromised membranes 
as shown by the arrows. In Figure 2-3B, the membrane of one vesicle has completely 
disintegrated and has formed a pore. Figure 2-3C shows a vesicle with a thinning portion 
of the membrane. Finally, in Figure 2-3D we see a membrane pore starting to form. 
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Figure 2-3: Cryo-TEM micrographs of PEO-PCL vesicles. Images were taken 12 hours after incubation at 
37C at (A) pH.7.4 and (B)-(D) pH 5.0.Arrows indicate areas of membrane degradation. Scale bar = 100 nm. 
 
Understanding the release at pH 5.0 is especially important for in vivo delivery to 
tumors because the extracellular environment of many tumors is acidic [30-32]. 
PolyGems would likely experience both acidic and physiological pH as they reach the 
tumor. 
 
2.4.4 In Vitro Cellular Uptake 
While it is known that polymersomes will partition into tumor tissue in vivo [24], 
cellular internalization of the vesicles at the tumor is desirable so the chemotherapeutic 
cargo can be released inside the cell in addition to the interstitial spaces where plasma 
clearance could be problematic. We visualized polymersome internalization by a cellular 
uptake study of blank polymersomes loaded with a hydrophobic porphyrin-based NIR 
fluorophore, PZn3, in the vesicle membrane. PZn3-based polymersomes have been 
utilized in the past to investigate polymersome uptake in dendritic cells (DCs) and DC 
trafficking in vivo [33-34]. In our study, Panc-1 cells were incubated with 50, 250, or 500 
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nM of PZn3-loaded polymersomes in 96 well plates for 12, 24, or 48 hours. A calibration 
was performed to relate the integrated intensity in wells to PZn3 concentration. Figure 
2-4 shows the concentration of internalized PZn3 as a function of incubation time. 
Vesicle uptake increased with an increase in the concentration of PZn3 as well as 
incubation time. In order to confirm that the internalization from the uptake study was not 
surface association, Panc-1 cells were incubated with 500 nM PZn3 for 12 hours and 
imaged on a confocal microscope with 1 μm z-slices. Figure 2-4C shows z-slices starting 
from the top of the cell and moving to the bottom. Vesicles are only observed internally 
and not on the cell surface. 
 
 
Figure 2-4: PolyGem internalization by Panc-1 cells. (A) Fluorescence intensity of PZn3-polymersomes 
internalized by cells in well plates corresponding to 48 hour time point. (B) Concentration of PZn3 uptake as 
a function of solution PZn3 concentration (n = 3). Error bars indicate standard deviation. (C) CLSM z-stack 
images of Panc-1 cells incubated with PZn3-polymersomes for 12 hours. Z-slices (Δz = 3 μm) are presented 
from left to right. Scale bar = 50 μm. 
 
The uptake study of PolyGems showed that vesicle internalization is a 
concentration- and time-dependant process with more internalization occurring for higher 
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polymersome number and longer incubation times. However, a relatively low percentage 
of vesicle internalization was observed.  A likely contributor is the stealth character 
imparted by the PEO block to the PolyGem, rendering the vesicles virtually invisible to 
Panc-1 cells. Another possible reason for low uptake could be a reduced cell surface 
area available for internalization due to cell adhesion on a tissue culture plate. Christian 
and coworkers observed a similar trend when incubating PZn3-polymersomes with 
dendritic cells. Negligible uptake was noticed for vesicles decorated with a PEO brush as 
compared to vesicles surface-conjugated with the HIV-derived TAT peptide [33]. 
 
2.4.5 In Vitro Cell Toxicity 
Panc-1 cell survival was determined by a clonogenic assay following 48 hour 
FreeGem or PolyGem exposure using varying drug concentrations (Figure 2-5). Panc-1 
survival is concentration dependent with an observed increase in cell kill as gemcitabine 
concentration was increased irrespective of the formulation used. A one log cell kill is 
observed at approximately 1 μM gemcitabine, irrespective of the formulation.  The only 
drug concentration where there was a significant difference in survival between 
FreeGem and PolyGems was at 0.05 μM gemcitabine (p = 0.048) where the PolyGem 
were more effective than the FreeGem. There was no significant cell kill using either 
blank polymersomes (0 μM PolyGem) or media-only treatment (0 μM FreeGem) as seen 
in Figure 2-5. 
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Figure 2-5: Panc-1 survival curve. Viability was determined after 48 hour treatment with varying 
concentrations of FreeGem or PolyGem, as measured by a clonogenic assay. Error bars indicate standard 
deviation (n = 3). * p < 0.05. 
 
To qualitatively assess cell toxicity, Panc-1 cells were imaged using differential 
interference contrast microscopy (DIC) following 48 hour exposure to media, 5 μM 
FreeGem, 5 μM PolyGem, or 2.5 μM blank polymersomes. These doses of PolyGem, 
FreeGem, and blank polymersomes were chosen to reflect the maximum concentration 
of gemcitabine delivered to Panc-1 cells in the clonogenic assay and to equate the 
concentration of PEO-PCL across the formulations (2:1 ratio of drug to polymer). Figure 
2-6A and Figure 2-6B demonstrate that application either of media or blank 
polymersomes, respectively, have no effect on cell viability since the cells are 
morphologically normal. Both 5 μM FreeGem and 5µM PolyGem treatments (Figure 
2-6C and Figure 2-6D, respectively), resulted in significant cell killing as observed by the 
presence of morphologically abnormal cells and cellular debris. 
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Figure 2-6: Cell phenotype as visualized by DIC. (A) Media control, (B) 2.5 μM empty polymersomes, (C) 
5 μM FreeGem, and (D) 5 μM PolyGem. Scale bar = 100 μm.   
 
Despite the low uptake without any targeting peptides, PolyGems performed at 
par with FreeGem (Figure 2-5). We believe that PolyGems released gemcitabine into the 
cell media, which was then internalized along with some vesicles via endocytosis and 
eventually leading to toxicity. 
 
2.5 Conclusion 
The true potential of PolyGems can best be determined in vivo where the drug 
kinetics are affected by all aspects of the tumor microenvironment, and the therapeutic 
ratio (TR) can be assessed. This ratio is optimally greater than one under in vivo 
conditions.  Gemcitabine-based chemoradiotherapy in pancreatic cancer currently has a 
very narrow TR, being very close to one [35-36].  The result is substantial toxicity to the 
GI tract.  We propose that this TR can be improved in future studies using the PolyGem 
technology. These nano-vesicles encapsulate and release gemcitabine over a prolonged 
period of time, which will likely be sufficient for non-specific accumulation of PolyGems 
27 
 
at the tumor site due to the EPR effect. A higher local concentration of drug in the tumor 
interstitial fluid can be expected because the polymersome prevents significant 
degradation of gemcitabine while trafficking to the tumor site. We predict that 
endocytosis of both free drug (due to release from the vesicles) and a portion of 
encapsulated drug will occur. The current findings – no decreased toxicity of 
gemcitabine using the encapsulated agent at equal concentrations of the free agent – 
are encouraging and support performing in vivo studies. Future studies will also focus on 
increasing efficacy by engineered internalization (i.e., using TAT-peptides conjugated to 
the polymersome surface) and targeting to specific cell surface receptors. 
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3 Light Responsive Polymersomes: 
Understanding the Light Dose 
Response of Soft Vesicles 
 
 
3.1 Summary 
Altering membrane properties of soft vesicles can be of great interest in the field of 
generating synthetic cells that can mimic biological function. It has been recently shown 
that polymersomes encapsulating a near IR porphyrin fluorophore in the hydrophobic 
membrane and dextran in the aqueous lumen undergo membrane instability when exited 
with visible light. With drug delivery as a motivating factor, causing this membrane 
stability to occur at low laser power and induced by near IR light can be quite beneficial. 
The work presented here describes a soft vesicle system that undergoes photorupture 
from 690 nm light at low light doses. Furthermore, we quantify the rupture of these 
vesicles by determining the release percentage of an encapsulated fluorescent 
molecule, sulforhodamine B. We compared the release from vesicles composed of soft 
and stiffer membranes and quantify up to 40% release from the soft vesicles after 100 
J/cm2 of 690 nm light delivery. 
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3.2 Introduction 
Polymersomes are bilayer vesicles self-assembled from amphiphilic copolymers 
[1]. Because of their robust chemical and mechanical properties, polymersomes have 
played an important role in therapeutic and diagnostic (theranostic) applications in drug 
delivery for cancer [2, 3], developing biomimetic systems to understand cellular 
processes [4], and acting as in situ mechanical stress sensors [5]. Polymersomes in the 
field of drug delivery have received particular attention. The large aqueous core and 
hyperthick hydrophobic membrane are capable of encapsulating significant 
concentrations of both hydrophilic and hydrophobic drugs, respectively, effectively 
providing a protective shell that increases drug circulation time in vivo [6]. There are 
several engineering challenges associated with synthesizing these polymersomes, and 
one of them is the release mechanism of the drug from the delivery vehicle. 
 
Several polymersome systems rely on internal release mechanisms such as pH, 
temperature, and redox potential to release the encapsulated cargo. The method of 
vesicle destabilization include altering the hydrophilicity of the polymer [7] or degrading a 
polymer block [6, 8, 9]. These internal release mechanisms take advantage of the tumor 
microenvironment, which is known to be acidic and reducing [10-12]. These harsh 
microenvironments cause polymersomes to undergo shape changes (vesicular to 
micellar) or increase the permeability of the membrane to facilitate drug diffusion across 
the hydrophobic membrane. While internal release mechanisms provide an escape route 
for drugs from the carrier, they are ultimately dependent on the highly variable 
microenvironment. The transition from internal release mechanisms to external 
mechanisms is advantageous because it could provide precise spatiotemporal control 
over drug delivery. 
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Recently, groups have reported light-mediated release from polymersomes. Light 
is an attractive external release trigger because it is noninvasive and can be directed at 
the desired site of release (eg. tumor). Typically, these systems contain light-activated 
linkers that combine the hydrophilic and hydrophobic blocks of the diblock copolymer. 
Upon excitation with light ranging from ultraviolet to near infrared, the linker cleaves and 
causes the vesicle to rupture [13, 14]. The synthesis and purification of such linker-
derived polymers can be challenging and often the energy required to cleave the linkers 
can be quite high and biologically unfeasible. 
 
Previously, our group reported a linker-free polymersome composite system with 
tunable sensitivity to light. Polymersomes encapsulating luminal solute (ferritin or 
dextran) and a membrane encapsulated meso-to-meso ethyne-bridged 
bis[(porphinato)zinc] (PZn2) chromophore exhibited membrane destabilization and 
rupture upon exposure to light [15-17]. The luminal solute functioned to stabilize the 
inner leaflet of the bilayer membrane, while PZn2 (a low fluorescent quantum yield 
chromophore [18]) acted as a local heating agent upon excitation. The resulting 
asymmetric membrane stretching due to heating effects during light excitation caused 
the vesicles to rupture. A limitation to our previous work was the excitation wavelength 
(blue-green light) and mode of light delivery (multi-line confocal lasers). The translation 
to a biologically relevant system with our platform would be challenging due to the strong 
absorption and scattering of blue-green light by hemoglobin, deoxyhemoglobin, melanin, 
and other proteins [19]. In the work presented here, we report an optimization of our 
existing platform where we cause light-induced rupture of micron-sized polymersomes 
with near infrared light at biologically relevant light doses. We compare the release of a 
model small molecule drug (sulforhodamine B) from two different polymersomes 
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composed of a soft (PEO14-b-PBD22, denoted OB14.5) and stiffer membrane (PEO30-b-
PBD46, denoted OB29). 
 
3.3 Materials and Methods 
3.3.1 Materials 
Poly(ethylene oxide)-poly(butadiene), PEO14-b-PBD22 (OB14.5, MW = 1800 
g/mol) and  PEO30-b-PBD46 (OB29, MW = 3800 g/mol) were purchased from Polymer 
Source (Montreal, Canada). A molecular weight series of Dextran (Leuconostoc 
mesenteroides and Leuconostoc spp.), Optiprep, and octyl β-D-glucopyranoside were 
purchased from Sigma Aldrich (St. Louis, MO). Methylene chloride (HPLC grade), 
phosphate buffered saline (PBS), and sucrose were purchased from Fisher Chemicals 
(Pittsburgh, PA). The meso-to-meso ethyne bridged (porphinato) zinc(II) dimer (PZn2, 
MW = 2123 g/mol) was synthesized by the Therien lab as previously described [18]. 
 
3.3.2 Polymersome preparation 
Polymersomes were prepared using thin-film rehydration. 1mM OB polymer 
(OB14.5 or OB29) with PZn2 at a molar ratio of 10:1 (polymer:fluorophore) were 
dissolved in methylene chloride. 200µL of this solution was deposited on a roughened 
Teflon strip and evaporated for 24 hours. Dextran at the desired molecular weight was 
dissolved at 5, 10, and 20 mg/mL in 290 mOsm sucrose. Sulfrorhodamine B was also 
dissolved in the sucrose solution with dextran at a concentration of 100mM. The 
resulting hydration solution was added to the OB-PZn2 composite film and hydrated at 
65ºC for 16 hours. Following the hydration period, the films were vortexed for one 
minute, which resulted in the spontaneous assembly of NIR emissive polymersomes, 
containing PZn2 in the hydrophobic membrane and Dextran and sulforhodamine B in the 
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aqueous core. The polymersomes were purified from unencapsulated Dextran and 
sulforhodamine B by centrifugation in a step gradient. The top layer contained the 
polymersome sample diluted in iso-osmotic PBS and the bottom layer contained a 
solution of sucrose and density gradient medium (80% sucrose/20% Optiprep by 
volume). The sample was spun at 10,000 RPM for 1 hour at 4ºC. The polymersomes 
migrated to the interface of the step gradient and were retrieved with a syringe. The 
polymersome sample was dialyzed against iso-osmotic PBS to remove any trace 
Dextran, sulforhodamine B, and Optiprep. 
 
3.3.3 Photodestruction of polymersomes and quantification of release 
A 690 nm diode laser (Model BWF2-690-1.0-400, B&W TEK Inc.) was used to 
illuminate the polymersomes in a well plate and cause photodestruction. The fluence 
rate was modulated to 200 mW/cm2 and delivered via a microlens tipped fiber. The total 
light dose varied was varied to 100 J/cm2. Post illumination, the released sulforhodamine 
B was separated from the polymersomes via centrifugation in Amicon centrifugal filters 
(NMWCO 10kDa). The fluorescence of the sulfrorhodamine B (λex = 480 nm, λem = 580 
nm) in the filtrate was measured using a Jobin Yvon Fluoromax-4 spectrofluorometer. 
100% release was measured by lysing the polymersomes with 30mM octyl β-D-
glucopyranoside. The fractional release (𝑓𝑟) was calculated using the following formula 
 
 𝑓𝑟 =
𝐹 − 𝐹0
𝐹𝑂𝐺𝑃 − 𝐹0
 Equation 3.1 
 
where 𝐹𝑂𝐺𝑃 is the fluorescence of the lysed polymersomes, 𝐹 is the fluorescence of the 
treated polymersomes, and 𝐹0 is the fluorescence of the untreated sample. 
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3.4 Results and Discussion 
3.4.1 Polymersome deformation upon illumination 
Polymersomes synthesized from OB14.5 polymer were subjected to both 
confocal illumination and 690 nm diode illumination to visualize membrane deformation 
and rupture (Figure 3-1B-C). OB14.5 polymersomes subjected to confocal illumination 
ruptured very quickly since the excitation wavelengths corresponded with the peak PZn2 
absorption (Figure 3-1A). Additionally, the laser energy per unit area (fluence rate) was 
extremely high because the laser spot size is on the order of hundreds of nanometers1. 
We transitioned the illumination to a 690 nm diode laser with a larger spot size (several 
centimeters) and illuminated the polymersomes for 250 or 500 seconds at 200 mW/cm2 
for a total light dose of 50 and 100 J/cm2, respectively. The 690 nm laser was chosen 
because it corresponded to the PZn2 absorption peak in the near infrared. During 
illumination, polymersomes underwent shrinkage and rupture and left behind debris, 
which can be visualized in Figure 3-3C. We next sought to quantify the rupture of the 
polymersomes by determining the release of a small fluorescent molecule, 
sulforhodamine B. The absorption of sulforhodamine B does not interfere with PZn2 
absorption (Figure 3-1A). 
 
                                               
1
 𝑟𝐴𝑖𝑟𝑦 =
1.22𝜆
2 𝑁.𝐴.
=
1.22(488𝑛𝑚)
2(1.3)
= 230 𝑛𝑚 
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Figure 3-1: OB14.5 polymersome deformation and rupture. Polymersomes contain 10 mol% PZn2 in the 
membrane and 100 kDa dextran at 10 mg/mL in the core. A) Normalized absorbance of PZn2 within OB14.5 
polymersomes and sulforhodamine B (SRB) in PBS. B) Polymersomes were exposed to confocal 
illumination (λex = 458, 488, 515, 543, and 633 nm) corresponding to the peaks in PZn2 absorption. Time-
lapsed confocal images show an intact polymersome followed by complete rupture. Scale bar = 10 µm and 
time stamp is given in seconds. C) Confocal micrographs of polymersomes illuminated with 690 nm diode 
laser at 200 mW/cm
2
 for a total light dose of 50 and 100 J/cm
2
. Polymer debris can be seen indicating 
polymersome rupture. Scale bar = 100 µm. The purple fluorescence corresponds to PZn2 emission. 
 
 
 
3.4.2 Dependence of dextran MW and concentration on SRB release 
We investigated the effects of dextran concentration and molecular weight on the 
release of sulforhodamine B from the aqueous core of OB14.5 polymersomes (Figure 
3-2). Three different molecular weights (10, 40 and 100 kDa) and concentrations (5, 10, 
and 20 mg/mL) of dextran were encapsulated within the polymersomes containing 10 
mol% PZn2 in the membrane. 
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Figure 3-2: Effect of dextran MW and concentration on SRB release from OB14.5 polymersomes. 
Polymersomes were illuminated at 200 mW/cm
2
 for a total light dose of 100 J/cm
2
. Dextran at three different 
concentrations and molecular weights were encapsulated in the aqueous core of polymersomes containing 
10 mol% PZn2 in the membrane. Fractional release was determined by scaling and normalizing SRB 
emission between the untreated case (0% release) and after addition of the non-ionic surfactant octyl-β-D-
gluopyranoside (OGP, 100% release). Error bars indicate standard deviation. N = 3 for each condition. 
 
A modest SRB release of about 15-20% was observed for 10 and 40 kDa at all 
concentrations after treatment with 690 nm at a light dose of 100 J/cm2. The fractional 
release increased to about 35-40% for the OB14.5 polymersomes containing 100 kDa 
dextran. Control polymersomes that contained either dextran or PZn2 (but not both) had 
negligible release. We found that the key determinant in polymersome rupture was the 
molecular weight of the dextran and not the concentration. Larger molecular weight 
dextrans are more amphiphilic than smaller dextrans and as such have the ability to 
interact with bilayer membranes and lower the membrane elastic modulus [21-23]. 
Previous work in our lab with OB29 polymersomes has shown that high molecular 
weight dextran lowered the membrane elastic modulus of polymersomes compared to 
control polymersomes containing no dextran, and that OB29 polymersomes were softer 
than the more rigid OB18 polymersomes [16]. We expect this trend to continue and that 
OB14.5 polymersomes are softer than OB29 polymersomes. 
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3.4.3 Light dose dependence on SRB release from OB14.5 and OB29 
polymersomes 
From the previous study, we identified that the dextran molecular weight and not 
its concentration within the polymersome determined the release from polymersomes. 
For subsequent studies, we investigated the light-dose response of OB14.5 and OB29 
polymersomes encapsulating 100 kDa dextran at 10 mg/mL with 10 mol% PZn2 in the 
membrane (Figure 3-3). After illuminating the samples with a 690 nm laser, we 
separated the intact polymersomes from the released SRB and quantified the relative 
amount of released SRB using fluorescence. 
 
Figure 3-3: Light-dose dependence on SRB release from OB14.5 and OB29 polymersomes. 
Polymersomes synthesized with 100 kDa dextran at 10 mg/mL in the lumen and 10 mol% PZn2 in the 
membrane. Polymersomes illuminated with 690 nm laser at 200 mW/cm
2
. A) Representative emission scans 
of SRB released from OB14.5 polymersomes upon treatment with 0, 10, 25, 50, and 100 J/cm
2
 of light. 
100% release was determined by adding a non-ionic surfactant, octyl-β-D-gluopyranoside. B) Release 
curves of SRB from OB14.5 and OB29 polymersomes after illumination. Error bars indicate standard 
deviation. N = 3 for each condition.    
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As shown in Figure 3-3A, SRB emission increased as a function of light dose for OB14.5 
polymersomes. A similar analysis was conducted for OB29 polymersomes as well. We 
scaled and normalized the emission scans to generate release curves as a function of 
light dose (Figure 3-3B). OB14.5 polymersomes released more SRB than OB29 
polymersomes at all light doses. We expect this to be the case since we calculated the 
Ka for OB14.5 polymersomes to be less than the Ka for OB29 polymersomes (i.e. 
OB14.5 formed softer membrane). OB29 polymersomes were better able to withstand 
the asymmetric stretching that occurred during excitation (and PZn2 heating). 
  
As a control, we measured the solution temperature post illumination to ensure 
that drastic fluctuations in temperature were not causing photorelease of SRB from 
polymersomes. After 100 J/cm2 of light delivery, the temperature of the polymersome 
solution increased by a maximum of 3ºC from room temperature. This result was initially 
surprising because theoretical calculations suggest that a system of water initially at 
room temperature needs a total of 130 J/cm2 of energy to completely vaporize 
(assuming a total mass of 0.05g water, which was our sample volume that was 
illuminated). However, this thermodynamic calculation requires an adiabatic system, 
which our system was not. The supplied radiative energy was absorbed by the porphyrin 
and converted to thermal energy. The net effect was a small increase in solution 
temperature and polymersome rupture. 
 
3.5 Conclusion 
We showed that giant polymersomes containing a porphyrin dimer (PZn2) in the 
hydrophobic membrane and dextran in the aqueous lumen ruptured in response to 690 
nm laser illumination. The polymersomes were responsive up to 100 J/cm2 of light 
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delivery, after which the release fraction started to plateau. We found that dextran 
molecular weight (and not concentration) is a determining factor in the release of 
sulforhodamine B from the aqueous lumen of polymersomes. 
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4 Light Responsive Nano-
polymersomes for the Photodynamic 
Therapy of Ovarian Cancer 
 
 
4.1 Summary 
Photodynamic therapy (PDT) requires the administration of a photosensitizer 
followed by illumination of diseased tissue with light to produce toxic singlet oxygen. 
Many photosensitizers currently being used in PDT are hydrophobic and require a 
delivery vehicle to increase their solubility and absorption both in vitro and in vivo. A 
standardly used construct is to embed the photosensitizer benzoporphyrin derivative 
monoacid A (BPD-MA) into liposomes. Here, we explore an alternative: the 
encapsulation and delivery of BPD-MA from a polymersome assembled from 
poly(ethylene oxide)–b-poly(butadiene) di-block co-polymer. We studied the intracellular 
uptake and toxicity of both the polymersomal and liposomal formulations and found that 
the polymersomes produced greater in vitro toxicity despite generating less singlet 
oxygen. The polymersomes served to protect BPD-MA from being leached and 
associated with serum proteins. In vivo studies showed that while BPD-MA-loaded 
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polymersomes and verteporfin had similar biodistribution profiles, the polymersome 
formulation performed at par with verteporfin in reducing tumor growth despite being 
present in a lower concentration within the tumor. 
 
4.2 Introduction 
Photodynamic therapy (PDT) is a clinically approved cancer therapy that can 
selectively kill malignant tissue. This therapy has been approved by the FDA for the 
palliation or treatment of diseases that include high-grade dysplasia (HGD) associated 
with Barrett’s Esophagus (BE), esophageal cancer, and non-small cell lung cancer. 
Additionally, clinical trials are being performed to determine the efficacy of PDT for 
bladder, mesothelioma, head and neck, pancreatic, and ovarian cancer, among other 
malignancies [1-6]. PDT is gaining wider acceptance in the clinic due to its demonstrated 
efficacy in treating more widespread superficial diseases, its lack of cumulative toxicities 
(and thus repeatability), and its suitability for combination with other therapeutic 
approaches [7-10]. 
 
PDT requires the administration of a drug (photosensitizer) and illumination of the 
diseased tissue [11, 12]. Light absorption by the photosensitizer produces reactive 
oxygen species, including singlet oxygen, that damage cellular components. Neither the 
photosensitizer nor the light is toxic by itself. The subcellular localization of 
photosensitizer is important for phototoxicity because the intracellular diffusion length for 
singlet oxygen is about 20 nm, and photodamage occurs very close to the site of the 
photosensitizer [13]. Additionally, when performed in vivo, PDT can lead to tumor cell 
death through the effects of treatment on host cells and tissues. For example, PDT 
damage of the microvasculature can contribute to therapeutic effect by shutting down 
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the blood vessels feeding the tumor [14, 15]. Treatment can also elicit an immune 
response that is associated with the release of inflammatory cytokines and active 
recruitment of leukocytes to the site of photodamage, potentially initiating the 
development of anti-tumor immunity [16]. 
 
Nanoparticle-based PDT has been studied for a wide variety of photosensitizers 
and nanovehicles. Lipid formulations of photosensitizers have received particular 
attention because this method of delivery has gained approval from the FDA in the forms 
of liposomal doxorubicin and daunorubicin, which were approved in the late 1990s. 
Liposomes can provide the necessary hydrophobic environment to solubilize 
hydrophobic photosensitizers, and additional modifications such as PEGylation to 
increase plasma circulation time and the conjugation of monoclonal antibodies for tumor 
targeting can render this class of nanoparticles quite potent [17-19]. Mir et al. integrated 
benzoporphyrin derivative monoacid A (BPD-MA) within targeted liposomes and showed 
tumor cell killing in an in vitro ovarian cancer model [19]. Polymeric-based nanoparticles 
have also been utilized for PDT and offer an advantage over lipids due to the variety of 
building blocks and surface functionality [20, 21]. Ding et al. used a non-covalently 
encapsulated protoporphyrin IX (PPIX) within polymeric micelles and showed a 
photosensitizer-dose response in the killing of lung cancer cells in vitro [22]. dePaula et 
al. created biodegradable nanospheres to encapsulate chloroaluminium phthalocyanine 
(AlClPc) and showed moderate phototoxicity in human fibroblast culture [23]. 
 
Verteporfin (benzoporhyrin derivative monoacid A, BPD-MA) is a second-
generation lipophilic photosensitizer that produces singlet oxygen at high quantum yield 
(ΦΔ =  0.78) [24, 25]. Current FDA-approved indications for verteporfin are limited to the 
treatment of subfoveal choroidal neovascularization (CNV) in age-related macular 
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degeneration (AMD) [26-28]. Ovarian cancer is the fifth leading cause of cancer deaths 
in women and represents another possible indication for PDT mediated by BPD-MA [29]. 
The work presented here discusses the efficacy and toxicity of BPD-MA encapsulated in 
polymersomes in treatment directed toward an ovarian cancer cell line and tumor model.  
Polymersomes are self-assembled bilayer vesicles synthesized from diblock copolymers 
capable of encapsulating large payloads of both hydrophilic and hydrophobic 
compounds [30, 31]. The capacity for carrying large amounts of hydrophobic drugs 
comes from hyperthick hydrophobic core of polymersome membranes, which is 
conveyed by the large molecular weight of the polymer used to assemble the membrane 
[32]. They also confer other advantages over liposomes including increased mechanical 
robustness and relative ease of surface functionalization [33-35]. Like liposomes, they 
have the capacity to encapsulate both hydrophilic and hydrophobic molecules. Here, we 
compare the performance of polymersomes made from poly (ethylene oxide) – b – poly 
(butadiene), designated OB14.5, loaded with 40% BPD (OB14.5-40% BPD), with that of 
verteporfin in a model for ovarian cancer.  
 
4.3 Materials and Methods 
4.3.1 Materials 
Reagents were obtained as follows: Singlet oxygen sensor green® (SOSG) from 
Life Technologies (Grand Island, NY); Benzoporphyrin derivative monoacid A (BPD-MA) 
from U.S. Pharmacopeia (Rockville, MD); VisudyneTM from Valeant Pharmaceuticals 
International, Inc. (Bridgewater, NJ); and Poly(butadiene(1,2)addition-b-ethylene oxide) 
(PEO(0.60k)-PBD(1.2k), OB14.5) from Polymer Source Inc. (Montreal, Canada). The 
meso-to-meso ethyne bridged (porphinato) zinc(II) trimer (PZn3) with a 9-methoxy-1,4,7-
trioxanonyl substituent on one aryl group and a more hydrophobic 3,3-dimethyl-1-
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butyloxy substituent on the other, was synthesized as previously described [36]. 
Methylene chloride, methylene blue for colony staining, phosphate buffered saline 
(PBS), sodium acetate trihydrate, and sodium chloride were purchased from Fisher 
Chemicals (Pittsburgh, PA). Centrifugal filter units were purchased from Millipore 
(Billerica, MA). 
 
4.3.2 Cell Line 
OVCAR-5 cells (Charles River, NCI Frederick, Frederick, MD) were maintained in 
RPMI 1640 media (Invitrogen) with 10% fetal bovine serum (FBS, Sigma) and 1% 
Pen/Strep. Media was supplemented with L-glutamine (1%) after three weeks.  Cells 
were cultured in a humidified incubator at 370C  under an atmosphere of 5% CO2. 
 
4.3.3 OB14.5-40% BPD Polymersome Preparation 
BPD-loaded polymersomes were prepared via thin film rehydration. Briefly, 1mM 
OB14.5 with BPD at a molar ratio of 1:0.4 (polymer:BPD) were dissolved in methylene 
chloride. 100 µL of the polymer-drug solution was cast on a roughened 1 cm2 Teflon 
surface in a scintillation vial and allowed to dry under vacuum for 24 hours. 1.5mL of 
PBS (for in vitro experiments) or 0.9% saline (for in vivo experiments) was added to the 
vial, and the composite film was sonicated for 60 minutes to generate nanometer-sized 
polymersomes containing BPD at a molar ratio of 40% in the membrane. Polymersomes 
were subjected to five cycles of freeze/thaw in liquid N2 and hot water to narrow the size 
distribution of polymersomes. The final drug concentration in polymersomes was 
measured by UV/Vis absorbance with an extinction coefficient of 0.044 cm-1 (µg/mL)-1 at 
690 nm. The polymersome sample was diluted to 20 ng/mL for in vitro experiments. Five 
to eight vials were prepared and combined for in vivo experiments. The final 
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concentration of 0.1 mg/mL for mice injections was prepared by concentrating the total 
volume from five to eight vials in 50 kDa Amicon centrifugation tubes. 
 
4.3.4 Verteporfin Preparation 
Visudyne™ (verteporfin for injection) was weighed and hydrated with 1mL of 
PBS (for in vitro experiments) or 0.9% saline (for in vivo experiments). The concentration 
of active compound (BPD) in verteporfin was measured monthly, and varied from 1.4 – 
1.9 mg BPD/100 mg. The active drug concentration was diluted to 20 ng/mL for in vitro 
experiments and 0.1 mg/mL for in vivo experiments. 
 
4.3.5 Determination of Singlet Oxygen Production 
Singlet oxygen sensor green® (SOSG) was protected from light and stored at -
20ºC. Fresh aliquots were prepared before the study. Singlet oxygen production was 
determined both in PBS and 5% serum. 180 µL of 1 µM BPD-MA as verteporfin or 
OB14.5-40% BPD was added in wells in a 96 well plate in triplicate. 20 µL of a 15 µM 
SOSG solution was added to each well. The samples were illuminated at 690 nm with a 
fluence rate of 40 mW/cm2. The total delivered light dose was 0, 5, 10, 20, 50, and 100 
J/cm2. 
 
4.3.6 Photodynamic Therapy 
A 690 nm diode laser (Model BWF2-690-1.0-400, B&W TEK Inc.) was used to 
deliver monochromatic light for in vitro and in vivo experiments. For in vitro experiments 
(clonogenic assays), the laser spot size was focused to 6 cm via a microlens-tipped 
optical fiber and an attenuator was used to modulate the fluence rate to 40 mW/cm2, as 
measured by a power meter  (LabMaster power meter; Coherent, Auburn, CA). OVCAR-
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5 cells were treated with OB14.5-40% BPD or verteporfin for 12 h in T-75 flasks to allow 
for drug internalization. Following the incubation period, cells were washed with Hank’s 
buffered saline solution (HBSS), moved to 6 cm dishes, and treated with 0, 5, 10, 15, or 
20 J/cm2 of light. For in vivo experiments, mice were injected via tail vein with 1 mg/mL 
BPD as either polymersomes or verteporfin. The fluence rate was modulated to 75 
mW/cm2 with a spot diameter of 1.1 cm to cover the mouse tumor. The total delivered 
light dose was 75 J/cm2. 
 
4.3.7 Clonogenic Assay 
OVCAR-5 cells were incubated with OB14.5-40% BPD or verteporfin at an 
equivalent BPD concentration of 20 ng/mL in low serum RPMI 1640 media (5% FBS, 1% 
Pen/Strep) for 12 hours. Following the incubation period, the cells were washed with 
HBSS to remove uninternalized drug. Trypsin (0.05%) was added to detach the cells 
from the flask and the cells were counted.  The PDT treatment is described above. A 
total of 2 x 105 cells were treated in a 6 cm dish with 0, 5, 10, 15 or 20 J/cm2 of 690 nm 
light at 40 mW/cm2. Following illumination, cells were plated in 10 cm tissue culture 
dishes in RPMI 1640 complete media (10% FBS, 1% Pen/Strep).  Cells were plated at 
concentrations of 102, 103, 104, or 105 cells per dish depending on the treatment 
condition. Dishes were incubated for 10-12 days and removed when the control dishes 
(no treatment) formed visible colonies. After removal of the media, a solution of 0.25% 
methylene blue (in 30% ethanol) was used to stain and fix the colonies. From plates that 
contained 10-300 colonies (a colony defined by 50 or more cells) the surviving fraction 
(SF) was defined as follows:  
 Plating efficiency = number of colonies formed by untreated cells / number of 
cells plated 
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 Surviving fraction = (number of colonies formed by treated cells) / (number of 
cells plated * plating efficiency) 
 
4.3.8 Cryogenic Transmission Electron Microscopy 
Cryogenic transmission electron microscopy was performed at the Krishna P. 
Singh Center for Nanotechnology at the University of Pennsylvania (Philadelphia, PA). 
Lacey formvar/carbon grids (Ted Pella) were rinsed with chloroform to dissolve and 
remove the formvar template. Grids were carbon coated with a Quorum Q150T ES 
carbon coater (Quorum Technologies, UK) and cleaned on both sides with 
hydrogen/oxygen plasma for 15 seconds using Solarus Advanced Plasma System 950 
(Gatan, Pleasanton, CA). 2 µL of either the polymersome sample or verteporfin was 
deposited on the lacey/formvar grid and inserted into a cryoplunger (Gatan Cp3, Gatan). 
The sample was blotted by hand with filter paper and plunged into liquid ethane. 
Samples were transferred to a Gatan CT3500TR cryoholder. The cryoholder was 
immediately inserted into a JEOL 2100 HRTEM (JEOL, Tokyo, Japan) operating at 200 
kV. Images were taken with an Orius SC200 digital camera. 
 
4.3.9 In Vitro Cellular Internalization and Serum Binding 
OVCAR-5 cells were separately incubated with 20 ng/mL verteporfin and 
OB14.5-40% BPD polymersomes for predefined lengths of time (15 minutes, 3 hours, 6 
hours, 12 hours, and 24 hours) in low serum RPMI 1640 media (5% FBS, 1% Pen/Strep) 
in 6 well plates. After the indicated incubation period, the cells were rinsed three times 
with RPMI 1640 media containing no serum to remove uninternalized drug. After the 
washing step, cells were removed from the wells with 0.05% Trypsin. A small aliquot 
was used to determine the cell density using a coulter counter. The remaining cells were 
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centrifuged to a pellet (1500 RPM, 5 minutes), and resuspended in 0.5 mL SOLVABLETM 
(Perkin Elmer) to completely digest the cells. The cells were digested for 4 hours at 50ºC 
in the dark in amber glass vials. After the digestion period, 0.5 mL of MilliQ water at 
room temperature was added to dilute and cool the tissue sample. 0.6 mL of the total 
volume was assayed for BPD-MA content using a Fluoromax-4 spectrophotometer 
(Jobin Yvon) (λex = 435 nm, λem = 630 – 750 nm). The peak fluorescence emission at 
690 nm was used to determine the concentration of BPD-MA in solution. The 
concentration of BPD-MA in solution was determined from a calibration curve. For serum 
binding experiments, verteporfin or OB14.5-40% BPD polymersomes were incubated at 
20 ng/mL BPD-MA with 5% calf serum at 37°C for predefined lengths of time (15 min, 3 
h, 12 h, and 24 h) and kept in the dark. After the incubation period was complete, the 
nanoparticles were separated from the serum protein using an amicon filter unit (MWCO 
1000kDa). The BPD content was measured via fluorescence at its emission peak of 690 
nm. As a control, verteporfin and OB14.5-40% BPD polymersomes were incubated with 
PBS. 
 
4.3.10 In Vivo Biodistribution 
4.3.10.1 Live-Animal Longitudinal Study 
Prior to drug administration, OVCAR-5 cells were injected subcutaneously on 
both the left and right shoulders of female Athymic nude mice (30 µL per injection at a 
density of 2.67 x 108 cells/mL). Mice were maintained on a chlorophyll-free diet (Harlan 
Laboratories) 10 days prior to imaging. After the tumors reached approximately 100 mm3 
in size, mice were injected via tail-vein with the following formulations of drug or 
fluorescent labels: verteporfin, OB14.5-40% BPD, OB14.5-40% BPD/2.5% PZn3 (dual-
labeled polymersome), and OB14.5-2.5% PZn3. The BPD concentration was maintained 
at 0.1 mg/mL for the formulations containing photosensitizer. The molar ratio of 
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BPD:PZn3 in the dual-encapsulated polymersome was kept at 16:1. At predefined time 
points post tail-vein injections (15 minutes, 1 hour, 3 hours, 8 hours, and 24 h), 
anesthetized mice (inhalation of isoflurane) were imaged on the LI-COR Pearl® Impulse 
Small Animal Imaging System (LI-COR Biosystems). BPD signal was captured in the 
700 channel (λex = 685 nm, λem = 720 nm) and PZn3 signal was captured in the 800 
channel (λex = 785 nm, λem = 820 nm). A white-light image was captured in the white 
channel. The imager resolution was set to 85 µm. Mice were imaged on the left and right 
sides to detect signal from the left and right tumors, and the ventral position to detect 
signal from the abdominal organs. Images were analyzed with the Pearl Impulse 
Software by drawing ROIs over the tumor, upper abdomen, and lower abdomen and 
recording the mean signal per area. 
 
4.3.10.2 End-Point Organ Biodistribution 
Prior to drug administration, OVCAR-5 cells were injected subcutaneously on 
both the left and right shoulders of female Athymic nude mice (30 µL per injection at a 
density of 2.67 x 108 cells/mL). After the tumors reached approximately 100 mm3 in 
size, mice were injected with equivalent dose of verteporfin or OB14.5-40% BPD at 0.1 
mg/mL BPD via tail vein injection. At predefined time points (15 min, 3 h, 6 h, 16 h, and 
24 h), the mice were anesthetized with an intraperitoneal injection of ketamine/xylazene. 
Whole blood was collected by cardiac puncture in sodium heparin-coated syringes.  
After confirmation of death, tumor, liver, intestines, and spleen were harvested for 
analysis of BPD-MA.  All organs were stored in cryo vials at -80ºC. Plasma was isolated 
as follows: whole blood was collected in 1 mL Eppendorf tubes and centrifuged at 1000 
RPM for 15 min at 22ºC. The top layer, which included plasma and some white blood 
cells, was carefully decanted and spun a second time at the same conditions as above. 
The purified plasma was collected and stored at -80 ºC.  
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During processing for spectrofluorometric analysis, tweezers were used to 
squeeze-out and remove any remaining food in the GI tract (intestines isolation). 30 – 50 
mg of tissue was weighed in 10 mm dishes and minced with surgical scissors. Minced 
tissue was placed into glass amber vials and 0.5 mL of SOLVABLETM (Perkin Elmer, 
Waltham, MA) was added to digest the tissue. Digestion took place for 4 hours at 50ºC 
in the dark. After the digestion period, 0.5 mL of MilliQ water at room temperature was 
added to dilute and cool the tissue sample. 0.6 mL of the total volume was assayed for 
BPD-MA content using a Fluoromax-4 spectrophotometer (Jobin Yvon) (λex = 435 nm, 
λem = 630 – 750 nm). The peak fluorescence emission at 690 nm was used to determine 
the concentration of BPD-MA in solution. Separately, calibration curves were generated 
to relate fluorescence emission at 690 nm to drug concentration for the organs of 
interest by adding known concentrations of verteporfin or OB14.5-40% BPD to tissue 
harvested from mice that received no drug treatment. 
 
4.4 Results and Discussion 
BPD-MA is a potent second generation hydrophilic photosensitizer [24]. Because 
of its poor solubility in aqueous environments, BPD-MA was formulated in a liposomal 
association and sold as VisudyneTM (verteporfin for injection). We have tested the 
encapsulation of BPD-MA in the hydrophobic membrane of polymersomes as an 
alternative delivery vehicle with the potential for high BPD-MA loading.  A schematic of 
singlet oxygen generation by polymersome-encapsulated BPD-MA is presented in 
Figure 4-1. 
 
57 
 
 
Figure 4-1: Polymersome delivery system. (a) Cartoon illustrating the encapsulation of BPD-MA in the 
hydrophobic core of the membrane of a polymersome. Excitation with 690 nm light causes BPD-MA to 
covert nearby ground-state triplet oxygen (
3
O2) into cytotoxic singlet oxygen (
1
O2). (b) Chemical structure of 
BPD-MA. (c) Chemical structure of the polymer OB14.5. 
 
 
4.4.1 Nanoparticle characterization 
Three different nanoparticle formulations were synthesized to understand the 
delivery and toxicity of the hydrophobic photosensitizer BPD-MA both in vitro and in vivo. 
VisudyneTM (verteporfin for injection) is a liposomal formulation of BPD-MA with an active 
drug fraction at 1.4 – 1.9 wt%. We developed a novel formulation of BPD-MA by 
encapsulating it in the hydrophobic membrane of OB14.5 polymersomes at a molar ratio 
of 1:0.4 (polymer:BPD), with an effective weight fraction of 16 wt% BPD. We also 
assembled OB14.5 polymersomes with a hydrophobic NIR emissive porphyrin trimer 
58 
 
(PZn3) [32, 36] at a molar ratio of 1:0.025 (polymer:PZn3), as well as dual-labeled 
OB14.5 polymersomes with both BPD and PZn3 at molar ratios of 0.4 and 0.025, 
respectively, for in vivo polymersome tracking. 
 
The structure of the nanoparticles was confirmed with dynamic light scattering 
(DLS) and cryogenic transmission electron microscopy (cryo-TEM) (Figure 4-2a and 
Figure 4-2b, respectively). DLS shows that the average hydrodynamic diameters for all 
three polymersome formulations (BPD only, PZn3 only, and dual BPD/PZn3) are around 
100 nm. The DLS results for verteporfin show an extremely polydisperse population 
ranging in size from 10 – 1000 nm. We imaged the structure of verteporfin and OB14.5-
40% BPD via cryo-TEM. Verteporfin is a liposomal formulation of BPD and consisted of 
a heterogenous population of micelles, sheets, and vesicles. OB14.5-40% BPD 
polymersomes, on the other hand, were predominantly spherical vesicles with a 
narrower size distribution from 30 – 200 nm. Thus the polymersomes offer the 
advantage that size and shape can be precisely controlled. Size of nanoparticles plays 
an important role in their in vivo efficacy. Work done by Anraku and coworkers measured 
the residence time of polymersomes of various sizes in the plasma, tumor, liver, and 
spleen of mice and found that the optimal polymersome size is between 100 – 150 nm 
for extended plasma circulation (circulation half-life of 23 hours) [37]. 
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Figure 4-2: Nanoparticle characterization. (a) Dynamic light scattering showing the hydrodynamic 
diameter of polymersomes containing BPD, PZn3, or both, and verteporfin. (b) Cryo-TEM micrographs of 
verteporfin and OB14.5-40% BPD. (c) UV/Vis absorbance spectra of nanoparticles containing BPD, PZn3, or 
both, and verteporfin. 
 
The encapsulation of the drug was confirmed via UV/vis absorbance spectroscopy 
(Figure 4-2c). BPD and PZn3 feature NIR absorbance bands centered respectively at 
690 and 794 nm. 
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4.4.2 In situ Singlet Oxygen Detection 
The phototoxicity from cell-localized verteporfin and OB14.5-40% BPD is a direct 
consequence of the ability of these nanoparticles to generate singlet oxygen. In order to 
quantify the singlet oxygen production from these nanoparticles, we utilized Singlet 
Oxygen Sensor GreenTM (SOSG) that captures singlet oxygen once it is released into 
solution and fluoresces. 
 
 
 
Figure 4-3: SOSG detection of Singlet Oxygen. Singlet oxygen was generated by irradiating BPD 
nanoparticles at 690 nm in the presence of SOSG at a fluence rate of 40 mW/cm
2
. (a) Detection of singlet 
oxygen formation by verteporfin and OB14.5-40% BPD at the same concentration of BPD (1µM). (b) 
Normalized SOSG signal per n vesicles from OB14.5-40% BPD and OB14.5-10% BPD.  
 
The assay can detect singlet oxygen only if it is able to diffuse out of the hydrophobic 
membrane of the polymersomes and into solution. We detected a greater concentration 
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of singlet oxygen from verteporfin than OB14.5-40% BPD at all light doses, potentially 
due to the loose association of BPD with the liposome and the protection of BPD by the 
hyperthick polymersome membrane. The high BPD-MA loading within the polymersome 
membrane may have also played a role in the lower singlet oxygen concentrations 
determined for OB14.5-40% BPD relative to that measured for BPD liposomes. It is also 
possible that the singlet oxygen that generated in the polymersome membrane diffused 
into the inner aqueous lumen where SOSG is not present. This could potentially reduce 
the SOSG signal. 
 
We also compared the singlet oxygen production from polymersomes loaded 
with 10% and 40% BPD in the membrane by normalizing to the vesicle number. In order 
to equate the BPD concentration, the 10% BPD polymersomes must be present in four 
times the number as the 40% BPD polymersomes. After normalizing by vesicle number 
(Figure 4-3b), OB14.5-40% BPD did produce greater singlet oxygen than OB14.5-10% 
BPD, as was expected. However, we did not observe a proportional difference in singlet 
oxygen production between polymersomes loaded with 10% and 40% BPD, possibly 
due to singlet oxygen quenching. Nevertheless, we chose OB14.5-40% BPD 
polymersomes for in vitro and in vivo studies with the objective of killing OVCAR-5 cells 
due to its higher production of singlet oxygen per vesicle. 
 
4.4.3 In vitro Cellular Internalization and Serum Binding 
Initial in vitro studies were conducted to assess BPD internalization into OVCAR-
5 cells after polymersome versus liposome (i.e. verteporfin) delivery (Figure 4-4a). 
OVCAR-5 cells were incubated with 20 ng/mL of BPD as either verteporfin or OB14.5-
40% BPD polymersomes in low serum (5% FBS) RPMI 1640 media for predefined 
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lengths of time (15 minutes, 3 hours, 12 hours, and 24 hours). The concentration of drug 
was measured using a spectrofluorometer and normalized to the total cell count. The 
amount of BPD per cell increased as a function of time for both verteporfin and the 
polymersomal formulation and leveled off after 12 hours. The total drug content was 
statistically greater for polymersomes than verteporfin after 12 and 24 hours of 
incubation. 
 
 
Figure 4-4: BPD uptake and serum binding. (a) BPD uptake per cell as a function of incubation time. * p = 
0.005 and ** p = 0.03. (b) BPD association to serum proteins as a function of incubation time. Incubation 
with PBS (no serum) had negligible signal (0.032 for OB14.5-40% BPD and 0.034 for verteporfin). ◦ p = 
0.02, ◦◦ p = 0.006, and ◦◦◦ p =  0.002. p-values were determined from a two-tailed student’s t-test with α = 
0.05. Error bars indicate standard deviation. 
 
Because BPD-MA is a hydrophobic molecule and is known to partition into LDL 
proteins in circulation [38], we next explored the serum association of BPD-MA in 
verteporfin and OB14.5-40% BPD polymersomes (Figure 4-4b). Verteporfin and OB14.5-
40% BPD polymersomes were incubated in PBS containing 5% FBS (low serum to 
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match the uptake study) for predefined lengths of time. A high MWCO membrane was 
used to separate the serum proteins from the nanoparticles and the presence of BPD 
was measured in the serum-containing filtrate. As shown in Figure 4-4b, BPD-MA 
partitions into serum proteins.  We ensured that the membranes were very selective to 
the serum proteins – no verteporfin or polymersomes went through. As an additional 
control, verteporfin and polymersomes were incubated in PBS without any serum. BPD-
MA did not leach into the surrounding buffer and remained associated with the 
nanoparticles. The decreased BPD fluorescence for serum proteins that were incubated 
with polymersomes suggested that the polymersomes were better able to protect the 
photosensitizer against serum leaching. Thus, the fraction of drug that is serum bound is 
much less for polymersomes than verteporfin. Based on differences in BPD association 
with serum at 12 h after incubation in verteporfin versus OB14.5-40%, together with the 
increased cell uptake of polymersome-delivered BPD at this time point, a 12 hour drug 
incubation period was chosen for further in vitro PDT studies. 
 
4.4.4 In vitro PDT of OVCAR-5 Cells 
OVCAR-5 cells were treated with 20 ng/mL of BPD for 12 hours as either 
verteporfin or OB14.5-40% BPD, followed by illumination at 690 nm. Cell survival 
decreased as a function of increasing light dose for both formulations (Figure 4-5a), thus 
the greatest difference in cytotoxic effect was detected at the highest light dose of 20 
J/cm2.  At this dose, PDT led to a surviving fraction of 0.008 for verteporfin and 0.002 for 
OB14.5-40% BPD (a 4-fold difference in survival). Controls with drug only and light only 
(20 J/cm2) showed no toxicity when compared to the case without treatment (surviving 
fractions of 1.05 and 0.98, respectively). 
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Figure 4-5: OVCAR-5 Surviving Fraction after PDT. (a) OVCAR-5 cells were incubated with 20 ng/mL of 
BPD-MA as either verteporfin or OB14.5-40% BPD polymersomes for 12 hours. The light dose was varied 
by modulating the illumination time. The fluence rate was held constant at 40 mW/cm
2
. * p = 0.014, ** p = 
0.036, *** p = 0.003. (b) OVCAR-5 cells were incubated with 20 ng/mL of BPD-MA for 12 hours as OB14.5-
10% BPD or OB14.5-40% BPD. ◦ p = 0.0007. The light dose in (b) was kept constant at 20 J/cm
2
 with a 
fluence rate of 40 mW/cm
2
. p-values determined from single factor ANOVA with the level of significance, α = 
0.05. Error bars represent standard deviation. 
 
Despite the lower measured singlet oxygen production by OB14.5-40% BPD compared 
to verteporfin (as shown in Figure 4-3), the polymersomes produced greater 
phototoxicity than verteporfin at all light doses. This effect could be the result of an 
increase in cellular uptake of BPD when delivered by polymersomes (see Figure 4-4a).  
Also, the greater toxicity of polymersome-mediated PDT could be related to high local 
concentrations of singlet oxygen that are produced by OB14.5-40% BPD. To test the 
latter hypothesis, we treated OVCAR-5 cells with equal BPD concentration (20 ng/mL) of 
OB14.5 polymersomes loaded with 10% or 40% BPD in the membrane. Results showed 
that a lower molar loading of BPD in the polymersome membrane (10% vs. 40%) 
produced very little phototoxicity even though the total BPD concentration was identical 
(Figure 4-5b). This suggests that highly localized concentrations of BPD as can be 
delivered by polymersomes can significantly benefit cytotoxicity, although this is 
associated with the caveat that high loading can promote inefficiencies in singlet oxygen 
production, perhaps due to quenching. 
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4.4.5 In Vivo Biodistribution 
We investigated the in vivo biodistribution of verteporfin and OB14.5-40% BPD 
polymersomes in nude Athymic female mice first via a semi-quantitative longitudinal 
imaging study using an NIR imager, and second with a quantitative end-point assay 
using a spectrofluorometer. 
 
For the longitudinal imaging study, BPD-MA was injected via tail vein at a dose of 
1 mg/kg as verteporfin or OB14.5-40% BPD. The fluorescence of BPD-MA was 
monitored in the 700 channel of the LI-COR Pearl® Impulse Small Animal Imaging 
System in the tumor (one each on left and right shoulders of the animal), as well as in 
the upper and lower abdomen, which corresponded to signal from mostly the liver and 
intestines, respectively. Based on our previous results showing that BPD-MA partitioned 
into lipophilic environments such as serum proteins (Figure 4-4), we also injected the 
mice with polymersomes encapsulating PZn3 to track the polymersomes themselves. 
PZn3 is a large and hydrophobic molecule that remains associated with the 
polymersome membrane for a prolonged length of time compared to BPD. OB14.5-40% 
BPD/2.5% PZn3 (dual-labeled) and OB14.5-2.5% PZn3 (singly-labeled) polymersomes 
were injected separately to track the separation of photosensitizer from polymersomes 
and polymersome location, respectively, in the 800 channel of the Pearl®. PZn3 has 
previously been used for the in vivo tracking of dendritic cells, and an in vitro and in vivo 
study of polymersomes localization [32, 34, 35, 39, 40]. 
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Figure 4-6: Longitudinal imaging of polymersomes formulated as OB14.5-40% BPD and/or OB14.5-
2.5% PZn3. (a) Mice received dual-labeled OB14.5-40% BPD/2.5% PZn3 polymersomes. Left column shows 
the left side of a mouse (arrow points to left tumor) and the right column shows the ventral side of the 
mouse. Emission has been pseudo-colored red (700 channel for BPD-MA) and green (800 channel for 
PZn3). (b) In mice that received verteporfin, OB14.5-40% BPD, or OB14.5-2.5% PZn3, ROIs were drawn 
over the tumors, upper abdomen and lower abdomen to measure the signal intensity per pixel (n = 2 – 3 
mice per condition). Error bars indicate standard deviation. Intensity values were normalized within each 
mouse to the values measured at 15 minutes after drug injection. 
 
Figure 4-6 shows the time-course of drug distribution in a mouse given dual-
labeled polymersomes. At early times (15 minutes and 1 hour) after injection, both BPD-
MA and the polymersome can be seen in the liver (yellow colocalization in the liver). 
After 1 hour, BPD-MA started to accumulate in the lower abdomen and was present in 
large amounts in the intestines (3 hours). After 8 hours, the lower abdomen was cleared 
of BPD-MA altogether. In animals that received verteporfin, OB14.5-40%, or BPD/2.5% 
PZn3, we quantified the signal intensity from the left and right tumors, upper abdomen, 
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and lower abdomen (Figure 4-6b). Based on these results, BPD-MA in verteporfin and 
OB14.5-40% BPD has a similar biodistribution with the exception of a delayed clearance 
of OB14.5-40% BPD from the upper abdomen (see 1 h timepoint). In tumors, it appears 
that BPD begins to be cleared at times after 3 h for both the liposomal and 
polymersomal formulations. In contrast, the PZn3 signal is very consistently seen in the 
tumor and lower abdomen, indicating that the polymersomes are staying in these 
locations. There is moderate clearance from the upper abdomen, but the clearance rate 
is much slower for the polymersomes than for the BPD. 
 
The imaging study provided a unique insight - that both the photosensitizer and 
polymersomes were reaching the tumor, and that the polymersomes were present for 
long times within the mice. Using an ex vivo spectrofluorimetric assay, the biodistribution 
of BPD-MA after liposome vs. polymersome delivery was studied in greater detail for 
each organ. Mice were injected with verteporfin or OB14.5-40% BPD at a dose of 1 
mg/kg. After predefined time points (15 minutes, 3 hours, 8 hours, 16 hours, and 24 
hours), blood was collected via cardiac puncture, then tumor, liver, spleen, and 
intestines were harvested from the euthanized animals. The aforementioned organs 
were analyzed for BPD-MA content by digesting these organs in a strong base and 
measuring the fluorescence of BPD-MA in the solubilized tissue (Figure 4-7). OB14.5-
40% BPD was more slowly taken up into the tumor than verteporfin as indicated by a 
significantly lower BPD-MA concentration at 3 h after injection of the polymersomes. 
Given the extremely similar plasma concentrations of drug for the formulations, it is likely 
that the delayed tumor uptake of BPD with polymersomes compared to verteporfin is 
due to the increased size of the polymersomes. Once present in the tumor, the BPD-MA 
concentration remained fairly equal between the two formulations. In the abdominal 
organs, the intestines (and to insignificant levels, the liver) were noted to have high BPD-
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MA uptake at 15 min after administration of polymersomes, but this cleared to levels 
equivalent to liposome-delivered BPD at 3 h post-injection. At the longer time points of 
16 and 24 h, the intestines, liver, and spleen had a small but significantly increased 
concentration of BPD-MA after administration of polymersomes compared to that 
resulting from liposome delivery of BPD. This is consistent with the longer retention of 
polymersomes in the upper and lower abdomen by in vivo imaging. Enhanced retention 
in abdominal organs could be related to polymersome interaction with immune cells such 
as macrophages due to their larger size. 
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Figure 4-7: Biodistribution of BPD-MA as delivered by verteporfin and OB14.5-40% BPD. At the 
indicated time points after injection, BPD-MA content was measured in the respective organs 
spectrophotometrically and calibrated to yield a concentration. Mice were injected with an equivalent dose of 
1 mg/kg BPD-MA as verteporfin or OB14.5-40% BPD. * p < 0.05 as determined from single factor ANOVA 
with the level of significance, α = 0.05. Error bars represent standard deviation. 
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4.4.6 In Vivo Response of OVCAR-5 Tumors 
Lastly, the effectiveness of PDT mediated by OB14.5-40% BPD polymersomes 
was tested in OVCAR-5 tumor xenografts. Once tumors reached approximately 50 mm3, 
mice were injected with an equivalent dose of 1 mg/kg BPD-MA as either verteporfin or 
polymersome via tail vein. In oncology studies, BPD-PDT is employed with a 3 h drug 
incubation to cause tumor cell damage, so we chose a 3 h interval before illuminating 
the tumors with 690 nm light [41, 42]. Tumors were treated with a fluence rate of 75 
mW/cm2 light for a total light dose of 75 J/cm2. We monitored tumor growth for 20 days 
after PDT. Tumor volumes were determined as follows: 
 
 𝑉 = 
𝜋𝐿𝑊2
6
 Equation 1 
 
where 𝐿 and 𝑊are the length and width of the tumor, respectively, and 𝐿 > 𝑊. Mice 
were sacrificed if the tumor volume exceeded 400 mm3. 
 
The tumors of mice that received either verteporfin or OB14.5-40% BPD, but no 
light, grew at a similar rate as those that received no light and no drug treatment (Figure 
4-8a). Moreover, animals that received light, but no drug (Figure 4-8b plot of “no 
treatment”) also grew at a similar rate to the other controls. In contrast, mice that 
received PDT (75 J/cm2 of 690 nm light) of their tumors (Figure 4-8b) showed a reduced 
tumor growth rate compared to all of the control groups. 
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Figure 4-8: PDT response of OVCAR-5 tumors. Nude athymic female mice were treated with saline (no 
treatment), OB14.5-40% BPD, or verteporfin at a dose of 1 mg/kg BPD. (a) The control groups received no 
light treatment. Each condition had three mice. (b) The light-treated group received 75 J/cm
2
 of light at a 
fluence rate of 75 mW/cm
2
. The no treatment group had three mice, whereas the OB14.5-40% BPD and 
verteporfin group each had five mice. Error bars are standard error of the mean.  
 
While the tumor response was similar for OB14.5-40% BPD and verteporfin, it 
should be noted that the concentration of BPD-MA in the tumor is a factor of 2 lower for 
the polymersomes (see 3 h time point on Figure 4-7). Thus, the OB14.5-40% BPD 
polymersomes provided equal phototoxicity with a lower dose of BPD than that delivered 
by verteporfin. 
 
4.5 Conclusion 
In summary, the second generation photosensitizer benzoporphyrin derivative 
monoacid A (BPD-MA) was encapsulated in the hydrophobic membrane of 
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polymersomes synthesized from the diblock copolymer, OB14.5 (PEO14-PBD22). The 
efficacy of this photosensitizer formulation was compared to an existing liposomal 
formulation, verteporfin. OB14.5-40% BPD was more potent at killing OVCAR-5 cells 
than verteporfin in vitro as determined from clonogenic assays. The polymersomes 
served as a protection against serum binding, thereby increasing the concentration of 
free BPD that was able to produce phototoxicity. In vivo, OB14.5-40% BPD 
polymersomes and verteporfin had similar biodistribution profiles. There was a lag in 
BPD-MA accumulation in the tumor at short times (3 h). Despite having a lower 
concentration in the tumor at 3 h, the polymersome formulation performed on par with 
verteporfin in studies of tumor response to PDT. 
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5 A Hydrodynamic Model of the Sized-
Based Separation of Polymersomes 
Using a Deterministic Lateral 
Displacement Microfluidic Device 
 
 
5.1 Summary 
We developed a hydrodynamic, forced-based computational model to understand 
the fractionation of polymersomes in a DLD microfluidic device. We found that the key 
parameter in determining the separation between two particles is the strength of the 
attraction between the cylindrical post and spherical polymersome. We developed a 
microfluidic DLD device synthesized from photolithographic techniques to experimentally 
separate polymersomes of known sizes. Using this model, we can correctly predict the 
fractionation of two polymersomes of different sizes (46 and 58 µm) in a DLD device. 
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5.2 Introduction 
Particle suspensions have traditionally been fractionated by size using 
chromatographic techniques. In this separation technology [1], porous beads are packed 
in a column and the particle suspension is driven through the stationary phase via a 
pressure gradient. Particles that are smaller than the pore size can travel through the 
beads via the tortuous pores, whereas larger particles travel through the void space 
created from the bead packing. The resulting fractionation occurs because of the size-
dependent path length taken by particles. A disadvantage to this method of fractionation 
is the “zone broadening” effect which stems from the fact that two particles of the same 
size may take two different paths: one longer and one shorter.  
 
The development of microfluidic devices for particle separation and fractionation is 
an interesting approach that combines hydrodynamics with chromatography. 
Deterministic lateral displacement (DLD) devices have been used to separate a wide 
range of particle sizes particles with submicron resolution [2, 3]. DLD devices utilize 
laminar flow through a periodic array of micron-sized obstacles that are rotated by a 
small angle with respect to the direction of flow. Particles that are larger than a critical 
size are “bumped” by the obstacles and are unable to cross-over into different lanes, 
whereas particles smaller than the critical size “zig-zag” through the device separating 
themselves from the larger particles. 
 
Theoretical approaches have been developed to understand the relationship 
between device geometry and particle separation [4-6]. In these approaches, particles 
follow streamlines until they interact with a post. Larger particles are unable to access 
streamlines that are close to the post due to steric hindrance effects and as such are 
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bumped by the posts. Smaller particles can travel along streamlines closer to the posts 
and can “zig-zag” between posts and migrate down the device at a different trajectory 
from larger particles. These approaches, however, do not take into account the vast 
majority of forces exerted on the particle by the fluid and posts and as such are unable 
to capture the physical motion of particle trajectories. 
 
Frechette and Drazer used a Stokesian Dynamics approach to understand particle 
trajectories in DLD devices [7]. Their model looked at the dynamics of a non-Brownian 
sphere suspended in a stationary fluid subject to a constant external force and a short 
range repulsive interaction. Simulations showed that particles subjected to varying 
forcing angles separated themselves based on size. The key difference between the 
simulations performed by Frechette and Drazer and the work done here is the inclusion 
of non-constant forces that are position dependent. Here we include non-constant 
hydrodynamic forces, torques, and van der Waals and steric repulsive forces that are 
coupled together via the grand mobility matrix. 
 
5.3 Materials and Methods 
5.3.1 Materials 
Poly(ethylene oxide)-poly(butadiene), PEO30-b-PBD46 (OB29, MW = 3800 g/mol) 
was purchased from Polymer Source (Montreal, Canada). Bovine serum albumin (BSA) 
and Pluronic F-127 were purchased from Sigma. Sylgard 184 silicone elastomer base 
and curing agent were purchased from Dow-Corning. PBS was purchased from Fisher. 
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5.3.2 Microfluidic Vesicle Preparation 
Micron-sized vesicles were prepared via a double emulsion technique using a 
glass capillary system as described previously [8-11]. The inner aqueous phase 
consisted of a solution of 290 mOsm sucrose. The middle organic phase consisted of a 
solution of 1 mg/mL OB29 in a mixture of chloroform and toluene (28:72 v/v). The outer 
phase consisted of 290 mOsm phosphate buffered saline (PBS) containing 1wt% BSA. 
The three solutions were cofocused into a single immiscible stream to generate double 
emulsions. These emulsions were collected in 2 mL of PBS in a 20 mL scintillation vial. 
The vials were loosely capped and placed on a gentle rocker for 1-2 weeks to allow for 
the organic layer to evaporate. The inner flow rate was maintained at 1.5 mL/hr, the 
middle flow rate at 7 mL/hr, and the outer flow rate was varied from 20-50 mL/hr to 
generate vesicles of various sizes. 
 
5.3.3 Microfluidic Mask Design 
The photomask was designed using AutoSketch®. The cylindrical posts are 100 
µm in diameter with an edge-to-edge spacing of 60 µm and grid rotation of 8º. 
 
5.3.4 Microfluidic Chamber Preparation 
The deterministic lateral displacement device was fabricated by replica molding 
on a patterned silicon wafer as the master and polydimethylsiloxane (PDMS) as the 
polymer. The master was fabricated by spinning a layer of negative photoresist (KMPR 
1050,MicroChem Corp., Brookline, MA) with a thickness of 88 µm onto a smooth silicon 
wafer, followed by a ramped soft bake period (65ºC to 115ºC at a rate of 15ºC every two 
minutes), and a continuous soft bake period at 115ºC for 15 minutes. The KMPR-coated 
wafers were exposed to UV light at a dose of 1520 mJ/cm2 using a contact mask aligner, 
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and post baked for seven minutes at 105ºC. The exposed wafer was developed with SU-
8 developer solution for 10 minutes, followed by an isopropanol rinse and drying. The 
device was fabricated by pouring PDMS (PDMS:curing agent 10:1 by weight) over the 
master and curing the elastomer for 12 hours at 65ºC. The device was cut out and 
separated from the master. Holes were punched out for the inlets and outlets with a flat-
tip stainless steel 20G needle. The PDMS device was plasma bonded to a glass cover 
slip. 
 
5.3.5 Microfluidic Chamber Operation 
Polymersome and PBS were loaded into one 3 cc and two 10 cc syringes, 
respectively. Polymersomes were introduced into the device via a syringe pump 
operating at a flow rate of 100 µL/hr. PBS was introduced into the left and right inlet 
channels using a second syringe pump operating at a flow rate of 1.5 mL/hr. These flow 
rates ensured laminarity in the microfluidic device. 
 
5.3.6 Determination of Forces 
We calculated the external forces exerted on the polymersomes by the fluid and 
cylindrical posts. Here we specifically considered the shear force exerted on the 
polymersome by the fluid, the torque exerted on the polymersome by the fluid due to the 
cylindrical posts, the van der Waals force between the polymersome and the posts, and 
the steric stabilization between the polymersome and posts. Our computational model 
assumed a two dimensional Stoke’s flow in the microfluidic device with negligible 
diffusion effects (𝑃𝑒 ≫ 1). Additionally, we ignored top and bottom edge effects in the 
calculations of particle trajectories. With these assumptions, we applied a streamline 
solution to determine the fluid velocity everywhere in the device. 
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Table 5-1: Definition of parameters in the computational model 
Parameter Definition 
𝑎 Polymersome radius, 𝜇𝑚 
𝜇 Water viscosity, 𝑁 ∙ 𝑠 ∙ 𝜇𝑚−2 
𝐹𝑖 Shear force on polymersome (𝑖 = 𝑥, 𝑦), 𝑁 
𝑣𝑖
𝑓𝑙𝑢𝑖𝑑
 Fluid velocity (𝑖 = 𝑥, 𝑦), 𝜇 ∙ 𝑠−1 
𝑈 Uniform fluid velocity, 𝜇 ∙ 𝑠−1 
𝑅 Post radius, 𝜇𝑚 
𝑑𝐺 Differential torque from post, 𝑁 ∙ 𝜇𝑚  
𝜏𝑟𝜃 Viscous stress, 𝑁 ∙ 𝜇𝑚
−2 
𝐻 Hamaker constant, 𝐽 
2ℎ Polymersome to post center to center distance, 𝜇𝑚 
𝛾 Compressibility of PEG brush, 𝑁 
𝑠 Polymersome to post edge to edge distance, 𝜇𝑚 
𝜏 Thickness of PEG brush, 𝜇𝑚 
 
Given the fluid velocity, the shear force on the polymersome was determined by invoking 
Stoke’s Law, 
 
 𝐹𝑥,𝑦 = 6𝜋𝜇𝑎𝑣𝑥,𝑦
𝑓𝑙𝑢𝑖𝑑
 Equation 5.1 
 
The expressions for the fluid velocities are given in the Appendix. In addition to the shear 
exerted on the polymersome by the fluid, the fluid flow also introduced a torque on the 
particles because the fluid is traveling at a slower velocity near the posts. We can once 
again take advantage of the streamline solution to the fluid flow field and determine the 
viscous stress on the polymersome. The expression for the differential torque on a 
polymersome due to one post is, 
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 𝑑𝐺 = 𝜏𝑟𝜃 ∙ 𝑎 sin𝜙 𝑑𝑆 Equation 5.2 
 
We can then integrate all of the differential torque components from the posts and add 
them together to obtain the final expression for the torque on the polymersome. The 
detailed calculations are presented in the Appendix. 
 
The two nonspecific interactions considered in this model were van der Waals 
and steric stabilization interactions. We approximated the interaction between the 
spherical polymersome and cylindrical post as a sphere-sphere interaction, where the 
expression for the van der Waals force has been determined by Parsegian [12], 
 
 𝐹𝑣𝑑𝑊 = −
32𝐻
3
𝑎3𝑅32ℎ
(4ℎ2 − (𝑎 + 𝑅)2)2(4ℎ2 − (𝑎 − 𝑅)2)2
 Equation 5.3 
 
The steric stabilization force is a well-known force in colloidal science [13]. It can be 
used to describe interactions between polymer-coated particles, such as cell-cell 
interactions in biology, or in our case, polymersome-post interactions. When two 
polymer-coated objects come close together, the polymer brushes on the surface 
compress and exclude the solvent. The resulting repulsive potential as described by 
Bell, Dembo, and Bongrand [14] can be represented as, 
 
 Γ(𝑠) =
𝛾
𝑠
𝑒−𝑠/𝜏 Equation 5.4 
 
86 
 
The repulsive force per unit area is simply the negative gradient of the potential with 
respect to separation distance. Invoking the Langbein approximation to estimate the 
interaction area between the polymersome and the post, the total repulsive force due to 
one post is, 
 𝐹𝑟 = 2𝜋𝑅𝛾𝑠 (
1
𝑠𝜏
+
1
𝑠2
)𝑒−𝑠/𝜏 Equation 5.5 
 
5.3.7 Particle Tracking 
The external forces (shear, torque, van der Waals, repulsion) as described in the 
previous section are functions of the position of the polymersome within the deterministic 
lateral displacement grid. Once these external forces are calculated for the interaction 
between the polymersome and each post, we sum over all of the posts to calculate the 
net external forces. The polymersome trajectory can be calculated using the 
hydrodynamic mobility function. A linear relationship describes the velocity of the particle 
to the external forces, 
 
 (ℱ̅) = −𝜇(?̿?)(?̅?) Equation 5.6 
 
 (?̅?) = −
1
𝜇
(?̿?)
−1
(ℱ̅) Equation 5.7 
 
The mobility matrix, (?̿̿̿̿?), is the inverse of the resistance matrix, (?̿?), and relates 
the applied external forces to the polymersome linear and angular velocity. The 
coefficients of (?̿?) are given in the Appendix and are described in detail by Brenner [15]. 
Brenner suggested that in the absence of a center of hydrodynamic stress, the 
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hydrodynamic resistance of a particle could be expressed in terms of three second-rank 
tensors, termed the Translation Tensor, the Rotational Tensor, and the Coupling Tensor 
[15]. These three tensors comprise the resistance matrix. Equation 5.7 implies that the 
inertial forces have been neglected, which is true in our case since the polymersomes 
have negligible mass, and that the fluid responds instantly to the changes in particle 
motion. 
 
Polymersome trajectories are calculated as follows. At every time step, the 
position of the polymersome is known within the grid. Based on the position we can 
calculate all of the forces exerted on the polymersome. As detailed in the Appendix, the 
Coupling Tensor is proportional to 1/ℎ4, and for this reason we calculate the resistance 
matrix for the polymersome-post pair that has the shortest center-to-center distance. 
Once (?̿?) and (ℱ̅) are known, Equation 5.7 can be solved for the particle linear and 
angular velocity. The polymersome position is updated based on the linear velocity, and 
the trajectory calculation is repeated at the next time step. The schematic of the 
geometry in the computational model is shown in Figure 5-1. 
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Figure 5-1: Top-view geometry of computational model. A polymersome of radius 𝒂 interacts with a 
periodic array of cylindrical posts of radius 𝑹. The array is rotated by angle 𝜽′ with post edge-to-edge 
distance 𝝀. The polymersome moves with linear velocity ?̅? and angular velocity ?̅?. 
 
5.4 Results 
5.4.1 Two-Body Simulation: Polymersome and Post 
We first studied the simplest case of a polymersome interacting with a single 
post. We use this example to illustrate the importance of the Hamaker constant (𝐻) and 
polymer chain compressibility (𝛾) in the model. The interplay between attraction and 
repulsion is important as it will dictate the particle trajectory and ultimately the separation 
of the polymersome within the DLD grid. We began by placing the particle far away from 
the post and introducing a fluid flow in the positive x-direction. Depending on the y-
position of the polymersome relative to the post, the polymersome will either clear the 
post completely following its unperturbed hydrodynamic trajectory, or the will come into 
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close proximity with the post and experience a combination of attraction and repulsion 
perturbing its hydrodynamic trajectory. We can derive an expression for the critical y-
position where the initial incident y-position is equal to the final y-position after 
encountering the post, 
 
 𝑦𝐻𝑦𝑑 = 𝑎 + 𝑅𝑝 −
𝑅𝑝
2
𝑎 + 𝑅𝑝
 Equation 5.8 
 
In the case where the particle’s trajectory is unperturbed by the post, 𝑦𝑖𝑛 ≥ 𝑦𝐻𝑦𝑑 and the 
final y-position is equal to the initial position, 𝑦𝑜𝑢𝑡 = 𝑦𝑖𝑛 . In the case where the 
polymersome can feel the post’s presence, 𝑦𝑖𝑛 < 𝑦𝐻𝑦𝑑 and 𝑦𝑜𝑢𝑡 = 𝑦𝐻𝑦𝑑 . Values of the 
Hamaker constant and polymer chain compressibility affect 𝑦𝑜𝑢𝑡 in the latter case when 
the polymersome can “feel” the post. 
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Figure 5-2: Single Polymersome-Post Interaction. a) Representative polymersome trajectory (motion of 
centers) with 𝑹 𝒂⁄ = 𝟐 for fixed 𝜸 = 𝟏𝟎−𝟕𝑵. Values of the Hamaker constant are 𝟏 × 𝟏𝟎−𝟏𝟒 𝑱 (solid line), 
𝟑 × 𝟏𝟎−𝟏𝟒 𝑱 (long dash), and 𝟓 × 𝟏𝟎−𝟏𝟒 𝑱 (short dash). b) Deviation from hydrodynamic trajectories as a 
function of varying Hamaker constant. 𝜸 = 𝟏𝟎−𝟕𝑵. c) Deviation from hydrodynamic trajectories as a function 
of varying and polymer chain compressibility. 𝑯 = 𝟑. 𝟕 × 𝟏𝟎−𝟏𝟒𝑱. 
 
Figure 5-2 illustrates the effects of varying the Hamaker constant and polymer chain 
compressibility on polymersome trajectory of different post to polymersome size (𝑅/𝑎) 
ratios. Figure 5-2a shows a representative trajectory of a polymersome at 𝑅 𝑎⁄ = 2. We 
see that increasing the Hamaker constant causes the polymersome to have a greater 
contact time with the post and have a lower 𝑦𝑜𝑢𝑡. We can represent deviations from the 
unperturbed hydrodynamic trajectory by normalizing 𝑦𝑜𝑢𝑡 with 𝑦𝐻𝑦𝑑, where a ratio of one 
implies a completely hydrodynamic interaction and values less than one indicate the 
relative strength of non-hydrodynamic interactions (i.e. attraction and repulsion). Figure 
5-2b and Figure 5-2c show the deviations from the unperturbed hydrodynamic trajectory 
as a function of varying the Hamaker constant and polymer chain compressibility. For all 
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size ratios, increasing the attraction increased the contact time between the 
polymersome and post, whereas increasing the repulsion decreased the contact time. 
The polymersome trajectory is more sensitive to variations in the Hamaker constant than 
variations in the polymer chain compressibility, and smaller polymersomes are even 
more sensitive to this change. For the case of 𝑅 𝑎⁄ = 2, increasing 𝐻 by a factor of five 
increased the perturbation from the hydrodynamic trajectory by 30%, whereas increasing 
𝛾 by a factor of 100 reduced the perturbation by 14%. We also found that a Hamaker 
constant of 5 × 10−14𝐽 imposed a very strong attraction between the polymersome and 
the post for 𝑅 𝑎⁄ = 3 such that the polymersome trajectory wrapped around the post. 
This result is physically unattainable in the experimental system and helped establish 
upper limits for values of the Hamaker constant. 
 
Since the trajectories are not very sensitive to changes in the polymer chain 
compressibility, we calculated the attractive and repulsive forces felt by the 
polymersome due to a single post for varying Hamaker constants at a constant 𝛾 (Figure 
5-3). Figure 5-3a and Figure 5-3b show the attractive and repulsive force, respectively, 
during the polymersome-post contact. Both forces are zero before and after the contact 
period. Figure 5-3c and Figure 5-3d show the maximum force felt by the polymersomes, 
which occurred at initial point of contact between the polymersome and post. 
Interestingly, we found that the repulsive force depends exponentially on 𝐻 . By 
monotonically increasing the Hamaker constant, we are exponentially increasing the 
repulsion experienced by the polymersome. 
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Figure 5-3: Attractive and repulsive forces during interaction. a) Repulsive force and b) attractive force 
felt by the polymersome for 𝑹 𝒂⁄ = 𝟐, 𝜸 = 𝟏𝟎−𝟕𝑵, and 𝑯 = 𝟎 𝑱 (black), 𝟏 × 𝟏𝟎−𝟏𝟒 𝑱 (red), 𝟐 × 𝟏𝟎−𝟏𝟒 𝑱 (green), 
𝟑 × 𝟏𝟎−𝟏𝟒 𝑱 (blue), 𝟒 × 𝟏𝟎−𝟏𝟒 𝑱 (pink), 𝟓 × 𝟏𝟎−𝟏𝟒 𝑱 (cyan). The arrow in (a) shows a dip in the forces and is 
indicative of the point where the polymersome breaks contact with the post. (c) Maximum repulsive force. (d) 
Maximum attractive force. The force vectors point radially outward, starting at the post center and ending at 
the polymersome center. 
 
5.4.2 Determination of Computational Grid Size 
The forces exerted on the polymersomes are a numerical sum of individual post 
contributions. While we can generate a post array of an arbitrary size and rotation, it is 
unnecessary to include force contributions from all posts. The hydrodynamic, repulsive, 
and attractive forces and the hydrodynamic torque are inverse power law functions of ℎ. 
As a result, posts that are far away from the polymersome will have negligible 
contributions to the net calculated force. Figure 5-4 shows the cumulative sum of the 
non-dimensional forces and torque as a function of the number of nearest posts that are 
included in the summation. 
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Figure 5-4: Cumulative sum of non-dimensional forces and torque on polymersome. A polymersome 
(a = 25 µm) was placed in the center of an array of posts with R = 50 µm, λ = 60 µm, θ = 8º. The calculated 
forces and torque are cumulative sums from post contributions, starting with the nearest post and working 
radially outward. The red dash represents the “equilibrium” value, which is the cumulative sum from all 
posts. 
 
As can be seen from Figure 5-4, the equilibrium force or torque value is reached after 
summation of a finite number of posts. The grid used to calculate the forces and torque 
contained a total of 7177 posts. The oscillatory behavior in the hydrodynamic forces (𝐹𝑥 
and 𝐹𝑦) are severely damped after summing over 100 nearest posts, indicating that (to a 
good approximation) the equilibrium value has been reached. The hydrodynamic torque 
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requires even fewer nearest posts (10) to reach equilibrium. The repulsive force is 
shown to be zero for all post numbers because the polymersome is not in physical 
contact with the post. This behavior suggests that the repulsive force contribution is a 
very short range interaction, and only comes from the single nearest post when the 
polymersome is on the order of 𝜏 µm away from the post. Similarly, the attractive force is 
also a short range interaction, with the polymersome feeling the presence of the nearest 
two posts. We can conclude from this study that it is unnecessary to include force and 
torque contributions from all posts within a microfluidic device. The power of this 
technique implies that one can study the separation of polymersomes within an 
extremely large grid size simply by calculating the force contributions from the nearest 𝑛 
neighbors.  
 
5.4.3 Experimental Results 
The microfluidic device contained three sections: inlet section, fractionation 
section, and collection section (Figure 5-5). The inlet section consisted of three inlets. 
The left and right inlets maintained the laminar flow throughout the device, while the 
center inlet introduced the polymersomes into the device. The fractionation section 
contained an array of cylindrical posts 100 µm in diameter with an edge-to-edge post 
spacing of 60 µm and grid rotation of 8º. The size-based separation of polymersomes 
occurred in this section. The collection section consisted of five outlets. The separated 
polymersomes exited the device via the outlets. 
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Figure 5-5: Microfluidic device schematic. The device contains three distinct regions: inlet, fractionation, 
and outlet. The polymersomes were introduced into the device through the center inlet channel. The left and 
right inlet channels helped maintain the fluid laminarity throughout the rest of the device. The fractionation 
channel contained an array of cylindrical posts with an edge-to-edge distance of 60 µm and post diameter of 
100 µm. The overall grid rotation was 8º. The outlet channels were used to collect fractionated 
polymersomes. It should be noted that the separation occurred in the left half of the device due to the grid 
rotation. 
 
Based on the grid rotation, the separation occurred in the left half of the device. Two 
sizes of polymersomes (46 and 58 µm) were separately introduced into the microfluidic 
device and the vesicle trajectories are shown in Figure 5-6. The 58 µm polymersomes 
followed the 8º path mapped out by the grid rotation and did not deviate from this path 
(Figure 5-6B). The 46 µm polymersomes were seen to deviate from the 8º path and 
cross over into different lanes (Figure 5-6A). 
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Figure 5-6: Polymersome trajectories in a 400 µm x 1600 µm region in the fractionation zone of the 
microfluidic device. a) Trajectories of 46 µm polymersomes. Scale bar = 200 µm. b) Corrected trajectories 
of 46 µm polymersomes, adjusted to start at the same point. c) Corrected trajectories of 58 µm 
polymersomes, adjusted to start at the same point. 
 
We calculated the average migration angle of the polymersomes within this region and 
found that there is a 4º separation between the 46 and 58 µm polymersomes (Figure 
5-7). This translated to the polymersomes being separated and collected in different 
collection lanes. 
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Figure 5-7: Polymersome trajectories within microfluidic device. a) Average migration angle of the two 
polymersomes as determined from experiment. Error bars indicate standard error or the mean. N = 12 for 46 
µm polymersomes and N = 11 for 58 µm polymersomes. b) Visualization of the endpoint of migration within 
the device based on the average migration angle. The shaded region indicates the range of migration as 
determined from the standard error. 
 
Using the Hamaker constant and polymer brush compressibility parameters 
established previously, we can use the model to predict the separation of 46 and 58 µm 
polymersomes (Figure 5-8).  
 
Figure 5-8: Predicting polymersome fractionation. a) 46 µm polymersomes and b) 58 µm polymersomes 
fractionated in a DLD device. Dashed lines represent computational simulations and solid lines represent 
actual experiments. 
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5.5 Conclusion 
We developed a hydrodynamic, forced-based computational model to understand 
the fractionation of polymersomes in a DLD microfluidic device. We found that the key 
parameter in determining the separation between two particles is primarily determined 
by the strength of the attraction between the cylindrical post and spherical polymersome. 
Interestingly, we found that the repulsive force experienced by the polymersome 
depends exponentially on 𝐻. Using this model, we can correctly predict the fractionation 
of two polymersomes of different sizes (46 and 58 µm) in a DLD device. 
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5.7 Appendix 
5.7.1 Fluid Velocity within the Microfluidic Device 
The Reynolds number for the steady motion of a sphere with velocity 𝑉  and 
diameter 𝐷𝑝 moving through a fluid with density 𝜌 and viscosity 𝜇 is 
 
 ReD =
𝜌𝑉𝐷𝑝
𝜇
 Equation 5.9 
 
For our present system, ReD ≪ 1 and we can reduce the full Navier-Stokes equation to 
the Stokes equation, 
 
 ∇𝑃 = 𝜇∇2𝑣 Equation 5.10 
 
and determine the velocity throughout the microfluidic device. Consider first the simple 
case of fluid flow past one cylinder. We can analytically determine the fluid velocity past 
this cylinder by invoking streamline solutions of known problems and the principle of 
superposition. The fluid velocity past a cylinder is a superposition of a uniform fluid 
velocity and a doublet flow as shown in Figure 5-9. 
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Figure 5-9: Streamlines solutions for velocity fields. a) Uniform 1D flow. b) Doublet flow. c) 
Superposition of (a) and (b) resulting in the solution for the non-lifting flow past a cylinder. 
 
The streamlines for the velocity fields presented in Figure 5-9 are given by 
 
 𝜓𝑢𝑛𝑖𝑓𝑜𝑟𝑚 = 𝑈𝑦 Equation 5.11 
 
 𝜓𝑑𝑜𝑢𝑏𝑙𝑒𝑡 = −
𝜅
2𝜋
sin𝜃
𝑟
 Equation 5.12 
 
Transforming Equation 5.11 into polar coordinates (or conversely Equation 5.12 into 
rectangular coordinates) and invoking superposition, the streamlines for Figure 5-9c are 
given by 
 
 
Ψ = 𝑈𝑟 sin𝜃 (1 −
𝑅2
𝑟2
) 
Ψ = 𝑈𝑦 (1 −
𝑅2
𝑥2 + 𝑦2
) 
Equation 5.13 
 
where the substitution 𝜅 2𝜋𝑈 = 𝑅2⁄  has been made. The velocity components can be 
calculated from the streamlines by taking the appropriate partial derivatives 
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 𝑣𝑥 =
∂Ψ
𝜕𝑦
= 𝑈 − 𝑈𝑅2
𝑥2 − 𝑦2
(𝑥2 + 𝑦2)2
 Equation 5.14 
 
 𝑣𝑦 = −
∂Ψ
𝜕𝑥
= −2𝑈𝑅2
𝑥𝑦
(𝑥2 + 𝑦2)2
 Equation 5.15 
 
Translating this solution to the problem of 𝑛 cylindrical posts in our microfluidic device, 
we can once again invoke superposition and sum over the 𝑛 posts 
 𝑣𝑥 = 𝑈 − 𝑈𝑅
2 ∑
(𝑥 − 𝑥𝑖)
2 − (𝑦 − 𝑦𝑖)
2
[(𝑥 − 𝑥𝑖)2 + (𝑦 − 𝑦𝑖)2]2
𝑛
𝑖=1
 Equation 5.16 
 
 𝑣𝑦 = −2𝑈𝑅
2 ∑
(𝑥 − 𝑥𝑖)(𝑦 − 𝑦𝑖)
[(𝑥 − 𝑥𝑖)2 + (𝑦 − 𝑦𝑖)2]2
𝑛
𝑖=1
 Equation 5.17 
 
where (𝑥𝑖 , 𝑦𝑖) refer to the coordinates of the cylindrical posts. We can see from Equation 
5.16 and Equation 5.17 that the x- and y-velocity components depend on all of the posts. 
The 1 𝑟4⁄  dependence, however, implies that far away posts have less of a contribution 
to the velocity at a given point than posts that are closer. 
 
5.7.2 Torque on the Polymersome 
Consider once again the solution to the problem of fluid flow past one cylinder. 
The rectangular velocities presented in Equation 5.14 and Equation 5.15 can be 
converted to cylindrical velocities and are given by: 
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 𝑣𝑟 = 𝑈 cos 𝜃 (1 −
𝑅2
𝑟2
) Equation 5.18 
 
 𝑣𝜃 = −𝑈 sin𝜃 (1 +
𝑅2
𝑟2
) Equation 5.19 
 
In order to calculate the torque on the polymersome due to the fluid, we must first 
determine the fluid viscous stress, which can be determined by taking the appropriate 
partial derivative of the fluid velocity: 
 
 𝜏𝑟𝜃 = 𝜇 [𝑟
𝜕
𝜕𝑟
(
𝑉𝜃
𝑟
) +
1
𝑟
𝜕𝑉𝑟
𝜕𝜃
] =
4𝜇𝑈𝑅2 sin 𝜃
𝑟3
 Equation 5.20 
 
The torque on the polymersome can be calculated by integrating the viscous stress over 
the surface of the particle. Every point on the surface of the polymersome can be 
parameterized with a position vector 𝑟 as show in Figure 5-10. 
 
 𝑟 = (𝑎 sin𝜙 cos 𝜃 + 𝑝)𝑖̂ + (𝑎 sin𝜙 sin 𝜃 + 𝑞)𝑗̂ + 𝑎 cos𝜙 ?̂? Equation 5.21 
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Figure 5-10: Post and polymersome geometry. Top view of cylindrical post located at the origin O with 
coordinates (0,0,0) and spherical polymersome located at P with coordinates (p,q,0). 
 
For the purposes of the torque calculation, we will assume that the top and bottom 
edges of the post do not affect the polymersome and as such the z-direction in the 
parameterization is neglected. The viscous stress can be restated in terms of the 
parameterization as follows: 
 
 𝜏𝑟𝜃 = 4𝜇𝑈𝑅
2
|𝑟𝑥𝑦 ∙ 𝑗̂|
|𝑟𝑥𝑦|
∙
1
|𝑟𝑥𝑦|
3 Equation 5.22 
 
The expression for the differential torque on the polymersome is given by: 
 
 𝑑𝐺 = 𝜏𝑟𝜃 ∙ 𝑎 sin𝜙 𝑑𝑆 Equation 5.23 
 
and the differential surface element on the polymersomes is: 
 
 𝑑𝑆 = 𝑎2 sin𝜙 𝑑𝜙𝑑𝜃 Equation 5.24 
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The final expression for the torque on the polymersome can be determined by combining 
Equation 5.22 – Equation 5.24: 
 
𝐺
= 4𝜇𝑈𝑅2𝑎3 ∫ ∫
𝑎 sin𝜙 sin𝜃 + 𝑞
[(𝑎 sin𝜙 cos 𝜃 + 𝑝)2 + (𝑎 sin𝜙 sin𝜃 + 𝑞)2]2
sin2 𝜙 𝑑𝜙𝑑𝜃
𝜋
0
2𝜋
0
 
Equation 5.25 
 
This integral was evaluated numerically using MATLAB. 
 
5.7.3 The Grand Mobility Matrix 
The resistance matrix (Equation 5.6) can be re-written to show all of the 
individual components as follows: 
 
 
[
 
 
 
 
 
𝐹𝑥
𝐹𝑦
𝐹𝑧
𝑇𝑥
𝑇𝑦
𝑇𝑧]
 
 
 
 
 
= −𝜇 [
𝑲 𝑫
𝑪 𝛀
]
[
 
 
 
 
 
𝑉𝑥
𝑉𝑦
𝑉𝑧
𝜔𝑥
𝜔𝑦
𝜔𝑧]
 
 
 
 
 
 Equation 5.26 
 
where 𝐹𝑖 is the external force acting on the polymersome, 𝑇𝑖 is the external torque acting 
on the polymersome, 𝑉𝑖 is the polymersome linear velocity, and 𝜔𝑖 is the polymersome 
angular velocity in the 𝑥, 𝑦, and 𝑧 directions. The four components of the resistance 
matrix consist of the translational dyadic (𝑲), the rotational dyadic (𝛀), and the coupling 
dyadic (𝑪), and the transpose of the coupling dyadic (𝑫). The resistance matrix for a 
sphere-cylinder system can be approximated by considering a sphere-sphere system. 
Detailed analysis of this system is presented by Brenner [15]. Let spheres 1 and 2 have 
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radii 𝑎1 and 𝑎2, respectively. Let the instantaneous center-to-center distance be 2ℎ and 
let ?̂?21 = −?̂?12  be a unit vector drawn from the center of sphere 2 to sphere 1. The 
sphere-sphere system can be described by the following system of equations: 
 
 
?⃑?1 = −𝜇(𝑲𝟏𝟏 ∙ ?⃑⃑?1 + 𝑲𝟏𝟐 ∙ ?⃑⃑?2 + 𝑫𝟏𝟏 ∙ ?⃑⃑?1 + 𝑫𝟏𝟐 ∙ ?⃑⃑?2) 
?⃑?2 = −𝜇(𝑲𝟐𝟏 ∙ ?⃑⃑?1 + 𝑲𝟐𝟐 ∙ ?⃑⃑?2 + 𝑫𝟐𝟏 ∙ ?⃑⃑?1 + 𝑫𝟐𝟐 ∙ ?⃑⃑?2) 
?⃑⃑?1 = −𝜇(𝑪𝟏𝟏 ∙ ?⃑⃑?1 + 𝑪𝟏𝟐 ∙ ?⃑⃑?2 + 𝛀𝟏𝟏 ∙ ?⃑⃑?1 + 𝛀𝟏𝟐 ∙ ?⃑⃑?2) 
?⃑⃑?2 = −𝜇(𝑪𝟐𝟏 ∙ ?⃑⃑?1 + 𝑪𝟐𝟐 ∙ ?⃑⃑?2 + 𝛀𝟐𝟏 ∙ ?⃑⃑?1 + 𝛀𝟐𝟐 ∙ ?⃑⃑?2) 
Equation 5.27 
 
In our simulation, sphere 2 will be held motionless and ?⃑⃑?2 = ?⃑⃑?2 = 0. For sphere 1, 
Equation 5.27 reduces to: 
 
 
?⃑?1 = −𝜇(𝑲𝟏𝟏 ∙ ?⃑⃑?1 + 𝑫𝟏𝟏 ∙ ?⃑⃑?1) 
?⃑⃑?1 = −𝜇(𝑪𝟏𝟏 ∙ ?⃑⃑?1 + 𝛀𝟏𝟏 ∙ ?⃑⃑?1) 
Equation 5.28 
 
Due to the interaction between the spheres, the four dyadic take the form of  
 
 
𝑲𝟏𝟏 = 6𝜋𝑎1 [𝑰 +
9
64
(
𝑎1
ℎ
) (
𝑎2
ℎ
) (𝑰 + 3?̂?12?̂?12)] 
𝛀𝟏𝟏 = 8𝜋𝑎1
3 [𝑰 +
3
64
(
𝑎1
ℎ
)
3
(
𝑎2
ℎ
) (𝑰 − ?̂?12?̂?12)] 
𝑪𝟏𝟏 =
9
16
𝜋𝑎1𝑎2 (
𝑎1
ℎ
)
3
[?̂?12 × 𝑰] 
𝑫𝟏𝟏 = −
9
16
𝜋𝑎1𝑎2 (
𝑎1
ℎ
)
3
[𝑰 × ?̂?12] 
Equation 5.29 
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where 𝑰 is the identity dyadic. If we define the center of the polymersome at (p,q) and the 
center of the post at (0,0), we can express the entire cross and dyadic products with the 
unit vector ?̂?12 in Equation 5.29 as follows: 
 
 
?̂?12 = −
𝑝
2ℎ
𝑖̂ −
𝑞
2ℎ
𝑗̂ 
?̂?12?̂?12 =
1
4ℎ2
[
𝑝2 𝑝𝑞 0
𝑝𝑞 𝑞2 0
0 0 0
] 
?̂?12 × 𝑰 = 𝑰 × ?̂?12 =
1
2ℎ
[
0 0 −𝑞
0 0 𝑝
𝑞 −𝑝 0
] 
Equation 5.30 
 
Finally, substituting Equation 5.30 into Equation 5.29 we obtain the final expression for 
the components of the resistance matrix: 
 
 
𝑲𝟏𝟏 = 6𝜋𝑎1 [
1 0 0
0 1 0
0 0 1
] +
9
64
(
𝑎1
ℎ
)(
𝑎2
ℎ
) [
1 + 3𝑝2 3𝑝𝑞 0
3𝑝𝑞 1 + 3𝑞2 0
0 0 1
] 
𝛀𝟏𝟏 = 8𝜋𝑎1
3 [
1 0 0
0 1 0
0 0 1
] +
3
64
(
𝑎1
ℎ
)
3
(
𝑎2
ℎ
) [
1 − 𝑝2 −𝑝𝑞 0
−𝑝𝑞 1 − 𝑞2 0
0 0 1
] 
𝑪𝟏𝟏 =
9
16
𝜋𝑎1𝑎2 (
𝑎1
ℎ
)
3 1
2ℎ
[
0 0 −𝑞
0 0 𝑝
𝑞 −𝑝 0
] 
𝑫𝟏𝟏 =
9
16
𝜋𝑎1𝑎2 (
𝑎1
ℎ
)
3 1
2ℎ
[
0 0 𝑞
0 0 −𝑝
−𝑞 𝑝 0
] 
Equation 5.31 
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The grand mobility matrix can now be determined by inverting the resistance matrix: 
 
 ℳ̿ = [
𝑲𝟏𝟏 𝑫𝟏𝟏
𝑪𝟏𝟏 𝛀𝟏𝟏
]
−1
 Equation 5.32 
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6 Summary of Major Results and 
Suggested Future Research 
 
 
6.1 Major Results with Respect to the Specific Aims 
 
Aim 1:  Develop controlled release nano-polymersome platform for the encapsulation 
and release of chemotherapeutic drug and determine toxicity in cancer cells. 
Results: A nano-polymersome system using a biodegradable and biocompatible block 
copolymer, PEO-PCL, was developed to encapsulate the chemotherapeutic 
drug gemcitabine, and released this cargo based on an external pH stimulus 
(acidic environment). We determined the efficacy of the PolyGems compared 
to the unencapsulated drug, FreeGem, and found that the PolyGems 
performed at par with the free drug with a total cell killing of 1 log at 1 µM 
gemcitabine dose. 
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Aim 2:  Quantify the release of an encapsulated fluorescent dye from giant 
polymersomes due to photo-initiated rupture. 
Result:  The rupture of giant polymersomes made from OB14.5 and OB29 polymers 
was quantified by detecting the released fraction of a fluorescent dye, 
sulforhodamine B, from the aqueous core of the vesicles. Polymersomes were 
irradiated using a 690 nm diode laser with a fluence rate of 200 mW/cm2 and a 
maximal light dose of 100 J/cm2. OB14.5 polymersomes released more 
sulforhodamine B than OB29 polymersomes because OB14.5 polymersomes 
have a softer membrane. 
Aim 3:  Encapsulate a photosensitizer in nano-polymersomes for photodynamic 
therapy and assess the in vitro and in vivo toxicity of the polymersomes. 
Result:  A second generation photosensitizer, benzoporphyrin derivative monoacid A 
(BPD-MA), was encapsulated in the hydrophobic membrane of OB14.5 nano-
polymersomes at a high molar loading ratio (40%). We compared the in vitro 
and in vivo toxicity of OB14.5-40% BPD to a liposomal formulation of BPD-MA, 
verteporfin. OB14.5-40% BPD polymersomes outperformed verteporfin both in 
in vitro toxicity assays and in vivo tumor response. The polymersomes serve to 
protect BPD-MA from being leached by serum proteins, and as such the 
concentration of BPD-MA that is unbound and able to generate singlet oxygen 
is greater than when verteporfin is used as the carrier vehicle. 
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Aim 4:  Develop a force-based model for understanding and predicting polymersome 
fractionation in a deterministic lateral displacement microfluidic device. 
Results: A hydrodynamic model was developed that incorporated shear, hydrodynamic 
torque, van der Waals attraction, steric repulsion as the forces and torques felt 
by the polymersome as it navigates a deterministic lateral displacement device. 
We found that the most sensitive parameter in fractionating the polymersomes 
is the Hamaker constant, which dictated the length of the “contact time” 
between the polymersome and the cylindrical post. We conducted experiments 
that fractionated polymersomes of two different sizes, and recapitulated this 
experimental result via a numerical simulation using the model that was 
developed. 
6.2 Further Investigations Towards the Development of Dual Drug 
Delivery Polymersomes for Combined Chemotherapy and 
Photodynamic Therapy 
The systemic toxicities associated with chemotherapy suggest that there is a 
strong need to provide local delivery of drugs to tumors. The work presented in Chapters 
2 and 4 of this dissertation outline two strategies for encapsulating chemotherapeutics 
and photosensitizers for PDT, respectively. Combining these modalities can have a 
synergistic effect on treatment outcomes.  
 
Several challenges must be considered for a dual-delivery system to be 
successful. An important question to answer consider is which therapy to do first – 
chemotherapy with polymersomes requires diffusion of the drug out of the aqueous 
lumen and into the tumor and PDT requires photosensitizer accumulation followed by 
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irradiation of the diseased tissue. One can allow for the drug to escape the 
polymersomes and cause cell damage, and then irradiate with light to generate singlet 
oxygen. However, the time scale for release of the chemotherapeutic drug might not 
match the time scale for accumulation of the photosensitizer, i.e. the drug is being 
released into the tumor while the photosensitizer is being cleared from the tumor. 
 
An alternate strategy would be to do PDT first with a short drug-light interval and 
cause vascular damage surrounding the tumor [1]. The tumor will lose its nutrient supply 
and undergo cell death. While this vascular shutdown is taking place, the 
chemotherapeutic can diffuse out of the polymersomes and cause direct cell death.  
 
The polymersome drug delivery system can be improved by adding targeting 
ligands onto the surface of the polymersome. The overexpression of EGFR on OVCAR-
5 cells can be exploited to preferentially accumulate polymersomes at the tumor site as 
opposed to other tissues. Work has been previously done conjugating cetuximab to 
BPD-MA, but this photoimmunoconjugate was not effective at killing OVCAR-5 cells [2]. 
It is possible that cetuximab hindered the ability of BPD-MA to effectively generate 
singlet oxygen. A polymersome system could be an improvement over the direct 
conjugation of an antibody to BPD-MA. The surface of polymersomes can be conjugated 
via peptide coupling reactions to include EGF binding domains (RGD domain). A newer 
approach would be to blend short surfactant-like peptides containing the binding domain 
with the polymer. Our lab developed has a family of oleosin mutants that resemble block 
copolymers [3]. Using molecular biology, one could include the RGD binding domain on 
the terminal end of the peptide and blend this targeting peptide with the polymer. 
  
  
114 
 
6.3 References 
 
1. Castano, A.P., P. Mroz, and M.R. Hamblin, Photodynamic therapy and anti-
tumour immunity. Nature reviews. Cancer, 2006. 6: p. 535-45. 
2. Abu-Yousif, A.O., et al., Epidermal growth factor receptor-targeted 
photosensitizer selectively inhibits EGFR signaling and induces targeted 
phototoxicity in ovarian cancer cells. Cancer letters, 2012. 321: p. 120-7. 
3. Vargo, K.B., R. Parthasarathy, and D.A. Hammer, Self-assembly of tunable 
protein suprastructures from recombinant oleosin. Proceedings of the National 
Academy of Sciences of the United States of America, 2012. 109(29): p. 11657-
11662. 
 
 
